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1 Summary 
While TGF- is able to regulate miRNA expression in numerous cell types, TGF--dependent 
changes in the miRNA profile of CD8
+
 T cells had not been studied before. Considering that 
TGF-β suppresses CD8+ T cell effector functions in numerous ways, we wondered whether 
induction of immune-regulatory miRNAs could add to the  known transcriptional effects of 
TGF-β on immune effector molecules. In this study, we used miRNA arrays, deep sequencing 
and qRT-PCR to identify miRNAs that are modulated by TGF- in human CD8+ T cells. 
Having found that the TGF--dependent downregulation of NKG2D surface expression in 
NK cells and CD8
+
 T cells does not go along with a corresponding reduction in mRNA levels, 
this pathway appeared to be a possible target of   TGF--inducible miRNAs. However, this 
hypothesis could not be confirmed by miRNA reporter assays. Instead, we observed that 
DAP10 transcription is suppressed by TGF- which in turn negatively affects NKG2D 
surface expression. In spite of promising preliminary experiments, technical difficulties 
associated with the transfection of primary NK cells and NK cell lines unfortunately 
precluded the final proof of this hypothesis. 
Instead, we focused on the TGF--induced changes in the miRNome of CD8+ T cells and 
confirmed the induction of the miR-23a cluster members, namely miR-23a, miR-27a and 
miR-24 by three different techniques. Searching for potential targets of these miRNAs which 
could contribute to the immunosuppressive action of TGF- in T cells, we identified and 
confirmed a previously unknown regulation of IFN- mRNA by miR-27a and miR-24. Newly 
generated miRNA reporter constructs further revealed that LAMP1 mRNA is a target of miR-
23a. Upon modulation of the miR-23a cluster in CD8
+
 T cells by the respective miRNA 
antagomirs and mimics, significant changes in IFN-γ expression confirmed the functional 
relevance of our findings. Effects on CD107a/LAMP1 expression were, in contrast, rather 
minimal. Still, overexpression of the miR-23a cluster attenuated the cytotoxic activity of 
antigen-specific CD8
+
 T cells. Taken together, these functional data reveal that the miR-23a 
cluster not only is induced by TGF-β, but also exerts a suppressive effect on CD8+ T-cell 
effector functions, even in the absence of TGF-β signaling. 
  
2 
 
2 Zusammenfassung 
Obwohl bekannt war, dass TGF- die miRNA Expression in zahlreichen Zelltypen moduliert, 
waren TGF- abhängige Veränderung des miRNA Profils in CD8+ T Zellen noch nicht 
untersucht worden. Da TGF-β die Effektorfunktionen von CD8+ T Zellen aber in vielfältiger 
Weise inhibiert, fragten wir uns, ob die transkriptionellen Effekte, die TGF-β bekanntermaßen 
auf Immuneffektormoleküle ausübt, noch durch die Induktion immunregulatorischer miRNAs 
ergänzt werden. Daher nutzten wir miRNA Arrays, Genomsequenzierungstechniken und 
Echtzeit-PCR um miRNAs zu identifizieren, welche in humane CD8
+
 T Zellen von TGF- 
moduliert werden. Die Beobachtung, dass die TGF--abhängige Herunterregulation der 
NKG2D Oberflächenexpression in Natürlichen Killerzellen und CD8
+
 T Zellen nicht mit 
einer entsprechenden Verringerung der mRNA Menge einhergeht, ließ zudem vermuten, dass 
dieser Signalweg über miRNAs reguliert werden könnte. Nach verschiedenen miRNA 
Reporterassays musste diese Hpothese jedoch verworfen werden. Stattdessen zeigte sich, dass 
TGF- die Transkription von DAP10 inhibiert was wiederum die Oberflächenexpression von 
NKG2D limitieren sollte. Trotz viel versprechender initialer Experimente scheiterte der 
letzgültige Beweis dieser Hypothese aber an der ungenügenden Transfizierbarkeit von 
primären NK Zellen sowie von NK Zelllinien. 
Daher konzentrierten wir uns im Weiteren auf die durch TGF- induzierten Veränderungen 
im miRNom von CD8
+
 T Zellen und konnten mit drei verschiedenen Techniken die Induktion 
des miR-23a Clusters (mit den einzelnen miRNAs miR-23a, miR-27a und miR-24) bestätigen. 
Auf der Suche nach potentiellen immunregulatorisch relevanten Zielgenen dieser miRNAs 
konnten wir erstmals eine Regulation von IFN- durch miR-27a und miR-24 nachweisen. Zu 
diesem Zweck generierte miRNA Reporterkonstrukte zeigten zudem, dass LAMP1 durch 
miR-23a reguliert wird. Nach Modulation des miR-23a Clusters durch die entsprechenden 
miRNA Antagomir und Surrogat-Konstrukte konnten wir auch in CD8
+
 T Zellen signifikante 
Veränderungen der IFN-γ Expression nachweisen und somit die funktionelle Relevanz 
unserer Befunde bestätigen. Die Effekte auf die Expression von CD107a/LAMP1 waren 
hingegen nur minimal. Trotzdem führte die Überexpression des miR-23a Clusters zu einer 
Verringerung der zytotoxischen Aktivität von antigenspezifischen CD8
+
 T Zellen. Zusammen 
genommen belegen diese funktionellen Untersuchungen, dass das miRNA-23a Cluster, 
welches durch TGF-β induziert wird, zur Hemung der Effektorfunktionen in CD8+ T Zellen 
beiträgt, und zwar sowohl in Gegenwart als auch in Abwesenheit von TGF-β. 
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3 Introduction 
3.1 CD8+ T cells  
CD8
+
 T cells are important effectors of our adaptive immune response towards virus (and 
other pathogens) infected cells, damaged cells as well as against tumor cells.  
3.1.1 Birth of a CD8+ T cell 
It all begins in the bone marrow where the hematopoetic stem cells reside. These multipotent 
cells give rise to pluripotent lymphoid progenitors which migrate through the blood stream 
and reach the thymus. In the thymus they lose their B cell potency through activation of 
Notch1 signaling (1). The resulting bi-potent (NK and T cell) progenitors (2) eventually give 
up their NK cell potency to form double negative (DN- no CD4 or CD8) T cell precursors. 
DN T cells then assemble a pre- T cell receptor (TCR) which contains either  and  (in 
almost 95% of cases) or, more rarely,  and  chains. The transition from the expression of 
pre-TCR to mature TCR involves recombination at the TCR- locus while undergoing 6-8 
cell divisions. At this stage, there is low surface expression of the TCR along with CD3/. Co-
receptor expression also begins by the expression of CD8 followed by CD4 resulting in a 
double positive (DP) T cell. DPs then prepare to audition for their survival in front of cortical 
thymic epithelial cells (cTECs).  
Their verdict to live is almost entirely based on the avidity/affinity of the TCRs towards the 
cTEC MHC-self peptide complexes. DPs with TCRs which do not interact or interact very 
poorly with the cTEC MHC-self peptide complexes lack necessary survival signals and die by 
neglect. If the TCRs show an intermediate affinity for cTEC MHC-self peptide complexes, 
they are induced to differentiate into mature single positive cells through positive selection. 
At the same time, cells which interact too strongly with the cTEC MHC-self peptide 
complexes are potentially dangerous if allowed to travel to peripheral organs as they can 
cause autoimmunity and are thus induced to undergo apoptosis (negative selection) (3-5).  
DPs differentiate into single positive cells by complicated silencing of the transcription of one 
of the co-receptors (CD4 or CD8). This process has been extensively reviewed by Littman et 
al. (6). Several hypotheses had been devised to explain this process, from an instruction 
model, to a selection model as well as a default model. In short, the instruction model 
proposed that the DP cells were instructed by the appropriate MHCs to terminate the 
expression of one specific co-receptor. The selection model stated that the DP cells randomly 
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selected either a CD4 or CD8 co-receptor and then waited for their chance of survival. Studies 
contradicting and supporting the 2 hypotheses surfaced (7-10). The default model however 
proposed that the DP cells chose to keep CD4 expression unless the TCR recognized a Class I 
MHC (Figure 1). 
 
Figure 1: T cell development in the thymus. Lymphoid progenitors enter the lymph nodes and progressively 
differentiate through various DN stages to DP, finally ending up as single positive T cells. (Image source: 
Germain R, Nature Reviews Immunology, 2002)  
 
However, later studies shed light on a new model where the DP cells gradually lose the 
expression of both co-receptors only to recover them to first express CD4 and later on CD8 
(hence a CD4
high, 
CD8
low
 stage) to progress towards a single positive stage. This model has 
been reviewed by Germain R (3). 
3.1.2 Activation of a CD8+ T cell 
A CD8
+
 T cell that is formed in the thymus emigrates into circulation and homes to the lymph 
nodes by the interaction of L-selectin with CCR7 (11). It is in the peripheral T cell area within 
the lymph nodes that the dendritic cells (DCs) deliver them the first kiss with their cognate 
antigen (12, 13). Upon activation, the naïve CD8
+
 T cells divide and differentiate into a 
phenotypically and functionally heterogeneous population of effector cells. Cytotoxic T cells 
(CTLs) are short-lived yet functionally more potent effector cells. They are thought to be 
derived from naïve cells that received a high level stimulation. On the other hand, those cells 
that received a low stimulation are likely the long-lived memory precursor effector cells (14, 
5 
 
15). Other studies have revealed that a single naïve CD8
+
 T cell can give rise to both CTLs 
and memory cells during the initial rounds of cells division through an asymmetric 
distribution of the transcription factor T-bet and proteasomal machinery, whereby the cells 
which receive more T-bet and less proteasomes become the short lived effectors (16, 17). 
Upon adequate antigenic stimulation, a naïve CD8
+
 T cell can undergo about 19 cell divisions 
in a week (18). Memory cells that persist in circulation or in secondary lymphoid organs can 
respond quickly and more effectively to repeated exposure to the antigen. CD28 receptor on T 
cells can interact with B7-1 and B7-2 receptors on antigen presenting cells to provide co-
stimulation. T cells can also receive a negative activation stimulus from B7-1 and B7-2 
through its CTLA4 receptors (19). A scheme summarizing the various signals a T cell 
receives from a DC or an antigen presenting cell (APC) and the signaling pathways that get 
kick-started are shown in Figure 2. 
 
Figure 2: T cell activation by an APC and the various signaling pathways. (Image source: 
http://www.sabiosciences.com/pathway.php?sn=TCR_Signaling). 
 
In addition to TCR and CD28 co-stimulation, a CD8
+
 T cell can get further stimulated by IL-
12, Type I Interferons as well as co-stimulated by 4-1BB, CD27 and OX-40 (14, 15, 20). IL-2 
is yet another CD8
+
 T cell activation cytokine, which signals via the CD25 receptor, whose 
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amounts are critical, where higher amounts favor CTL phenotypes and lower amounts favor a 
memory phenotype (21, 22). This is the reason why in vitro stimulation of T cells using anti-
CD3 and anti-CD28 immobilized on beads efficiently activate and expand them. Once 
activated and expanded, the CD8
+
 T cells upregulate CXCR3 to exit the lymph nodes to 
migrate towards the site of infection or action (23). 
3.1.3 Functions of CD8+ T cells  
Based on expression of CCR7, circulating CD8
+
 memory T cells can be further divided into 
two functionally distinct subsets with distinct functional properties: CCR7
+
 central memory 
cells (TCM) express lymph-node homing receptors and lack immediate effector function, but 
efficiently stimulate dendritic cells and differentiate into CCR7
-
 effector memory cells (TEM) 
cells upon secondary stimulation. CCR7
-
 effector memory cells express receptors for 
migration to inflamed tissues and display immediate effector function (24). The major effector 
function of an activated CD8
+
 T cell is to kill its target cell which presents its cognate peptide 
on a self MHC class I molecule. The target cells are usually virus infected cells, cells with 
intracellular pathogens and tumor cells. Target cell lysis is achieved through 3 mechanisms, 
death-receptor mediated, lytic granule mediated, and cytokine mediated.   
3.1.3.1 Death receptor mediated killing 
Activated CD8
+
 T cells express death ligands like Fas ligand (CD178) which can engage Fas 
receptor (CD95) on target cells and initiate caspase dependent cell death through FADD (Fas 
associated death domain). FADD activates Caspase 8 which in turn directly kicks on a 
cascade of effector caspases (in type I cells). In so-called type II cells, Fas-mediated apoptosis 
is further amplified by activation of caspase 9 via BID, BAX and release of mitochondrial 
cytochrome (followed by Caspase 3) activation (25). Either mechanism can lead to the death 
of the target cell (Figure 3) – unless the cell is protected by anti-apoptotic proteins like Bcl-2, 
Bcl-xL, FLIP, IAP, XIAP etc. which are often overexpressed in cancer cells. The same 
mechanism and thus also the same anti-apoptotic strategies apply to cell death induction via 
TNF-related apoptosis-inducing ligand (TRAIL) (26, 27).   
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Figure 3: Target cytotoxicity through Fas by CTLs. FasL on CTLs engages Fas on the target cells and 
initiates Caspase mediated apoptosis. (Image source: Bleackley et al, Nature Reviews Immunology, 2002.) 
 
3.1.3.2 Granule mediated killing 
Upon activation via the TCR, a CD8
+
 T cell starts to armor itself by stocking up cytotoxic 
granules. These granules where all the components bath in an acidic pH contain 
predominantly perforin, granzymes, calreticulin and granulysin (28). These granules are 
surrounded by several proteins including lysosomal membrane proteins LAMP1 and LAMP2. 
When a granule-loaded CTL encounters a target cell, it forms an immunological synapse 
where the TCR interacts with the cognate peptide presented on the MHC of the target cell. 
This sets the stage for a granule attack. Microtubule rearrangement and directional procession 
of the granules then follow which result in the secretion of granule components into the 
synapse. Perforin and granzymes (mainly A and B) form the fatal duo. It is a matter of debate 
how granzymes enter the target cells. A role for mannose-6-phosphate receptor (which is 
involved in granzyme packaging into granules) has been proposed by various studies but later 
studies showed that it was not essential. This dichotomy was later revealed to be due to the 
use of monomeric granzymes, which does not require mannose-6-phospate receptor for target 
cell entry, in those experiments. Under physiological conditions, granzyme B is released 
complexed to proteoglycans whose entry into target cells can be mediated by mannose-6-
phosphate (29, 30). Another widely accepted mechanism is that perforin forms pores on the 
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target cell through which the granzymes enter (31). These 2 mechanisms are depicted in 
Figure 4. 
 
Figure 4: Release of cytotoxic granules and entry of granzymes into the target cell. (Image source Bleackley 
et al, Nature Reviews Immunology, 2002.) 
 
The best characterized granzymes are the most expressed A and B forms. Granzyme B can 
cleave proteins after aspartate residues and activates the caspase cleavage cascade by 
activating caspase 3 and 8 to inflict target cell apoptosis (32-34) as depicted in Figure 5. 
Cytotoxic granule mediated killing is faster because of the quick release of pre-formed 
granules. However some studies indicate that there are pre-existing distinct granules in CTLs 
that store Fas ligand which can be exposed quickly. This would result in 2 waves of Fas 
ligand exposure (35). 
Such potent cytolytic molecules can potentially harm the T cells during storage and delivery. 
The granule essentially prevents such a catastrophe by maintaining an acidic pH (about 5.5). 
Calreticulin plays an important role by interacting with perforin monomers keeping them 
apart within the granules and is later dissociated after exocytosis enabling perforin pore 
formation (36). Another study highlighted the importance of serine protease inhibitor 6 which 
maintains granule integrity by inhibiting granzyme B activity within granules (37). 
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Figure 5: Initiation of caspase dependent and independent cell death by granzyme B. Once internalized by 
the target cell, granzyme B cleaves caspase 3 and 8 to initiate apoptosis. It can also initiate a BID, BAX and 
mitochondrial cytochrome mediated cell death pathway. (Image source Bleackley et al, Nature Reviews 
Immunology, 2002.) 
 
Structural integrity and stability of the cytotoxic granules is also contributed by heavily 
glycosylated proteins that line the granules, namely LAMP (lysosome associated membrane 
protein) 1 and 2 (38). LAMP1 (also called CD107a) is a highly abundant lysosomal protein 
with its N terminal directed towards the granular lumen and spanning the granule membrane 
once. Intriguingly, the function of LAMP1 and LAMP2 within the lytic granules is largely 
unknown. Several studies indicate the protective function of LAMP1 and LAMP2 on the 
granule membrane from the acid hydrolases within, due to their extensive glycosylation. 
LAMP1 deletion in mice however led to a compensatory effect by an increase in LAMP2 
production and almost no effect on lysosomal functions (39). Double (LAMP1 and LAMP2) 
knockout was however embryonically lethal in mice (40). Still, the importance of LAMP1 in 
cytotoxic granules was recently uncovered when researchers demonstrated that silencing of 
LAMP1 resulted in impaired granule mediated NK cell cytotoxicity (41). This was due to the 
inefficient delivery of perforin rather than granzymes into the granules. In the same study 
using time lapse imaging, LAMP1 was shown to play a vital role in granule mobility as well.  
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3.1.3.3 Cytokine mediated toxicity 
Upon TCR activation, downstream signaling mediated through T-bet and eomesodermin 
(Eomes) drives the synthesis of various effector molecules, including Interferon-gamma (IFN-
) and TNF-. It has to be noted that T cells that are activated need not elicit all of the 
aforementioned toxicity mechanisms. For instance, virus specific CTLs are good producers of 
IFN- but show poor granule expression. This non-cytolytic control is particularly important 
in the clearance of virus infections with minimal self tissue damage. The only member of the 
type II class of interferons, IFN- inhibits viral replication within cells. It also exerts potent 
anti-proliferative, anti-angiogenic as well as pro-apoptotic anti-tumor effects (42-44). IFN- 
also induces MHC-class I expression on tumor cells which makes them susceptible to CD8
+
 T 
cell mediated killing (45). The efficacy of IFN- in clearing tumors has recently been 
demonstrated where the adoptive transfer of tumor specific CD4
+
 T cells induced tumor 
regression in a patient with epithelial cancer (46). 
Uncontrolled T cell activation as well as inefficient contraction of an immune response after 
an infection has been cleared can be detrimental to our body. Hence several immune 
inhibitory check points are placed during an immune response. One of the cytokines that play 
an important role in preventing autoimmune responses and restoring homeostasis after 
infection is TGF-. 
3.2 Transforming growth factor- (TGF-) 
In 1983, TGF- was first purified from human platelet extract (47). Since then, a large group 
of structurally related cell regulatory proteins have been discovered and have formed a group 
called the TGF- superfamily named after the founding member. This superfamily has been 
broadly grouped into 4 major sub-families, the decapentaplegic-Vg-related (DVR) related 
subfamily (including the bone morphogenetic proteins and the growth & differentiation 
factors), activins & inhibins, TGF-s and a group encompassing various other divergent 
members (48, 49). It is believed that the TGF-β system originated about one billion years ago, 
before the divergence of arthropods from vertebrates, and has then adapted over the years to 
regulate newly emerged systems in higher organisms (50). In mammals, TGF-exists in 3 
homologous isoforms, TGF--1, 2 and 3 which are encoded by different genes (51). The term 
TGF- is widely used (including in the study described in my thesis) to refer to TGF-1. 
Right from its discovery TGF- was a bit of a mystery molecule because of the large 
spectrum of divergent effects it had on several cell types, many of them depending on the 
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cellular context. It could inhibit and promote cell growth, suppress pre-malignant cells but 
promote metastatic ones, enhance pluripotency as well as promote differentiation, etc. This 
lead to the expectation of a complicated pathway until the relatively simple pathway mediated 
by SMAD proteins was uncovered. 
TGF-β is synthesized in a pre-pro-form. While the pre-region holds a signal peptide, the pro-
TGF-β is processed in the Golgi by a furin-like peptidase (52) where the N-terminus pro-
peptide of the immature protein is removed. A homodimer of the resulting latency associated 
protein (LAP) is non-covalently associated with a homodimer of mature TGF-β and is called 
latent TGF-β or the small latent complex (SLC). The SLC is either secreted as itself or 
associated with latent TGF-β-binding protein (LTBP) as a large latent complex (LLC). LTBP 
enables the targeting of TGF-β to the extracellular matrix (53). Latent TGF-β cannot bind to 
its receptors unless it is liberated from LAP and LTBP. In vitro, this can be achieved using 
extremes of pH, heat, or several proteases (53). In vivo, proven mechanisms for activation 
include proteolytic activation by transglutaminase, conformational change of LAP through 
physical interaction with thrombospondin and mechanical traction via αvβ6 integrins on 
epithelial cells (54-56). Having said so, very little is known about the expression of TGF- 
transcription of its message and protein synthesis. The vast untranslated regions (UTRs) in the 
TGB- mRNA point towards post transcriptional regulations that are yet to be uncovered in 
different cellular contexts (57). In our immune system, TGF-1 is the predominant isoform 
that is expressed.  
TGF- mediates its effects through the type I (ALK5) and type II (TGFβRII) receptors. The 
active form of TGF-β binds TGFβRII. While TGF-β1 and TGFβ3 bind to TGFβRII with high 
affinity, strong binding of TGF-β2 to TGFβRII occurs in the presence of membrane bound 
betaglycan, also known as TGFβRIII (58). The active TGF-β dimer binds to the tetrameric 
ALK5 and TGFβRII receptor complex to initiate cell signaling (59). Ligand binding brings 
the type II receptor close to the type I receptor which then becomes activated. Activated type I 
receptor phosphorylates intracellular Smad proteins. p-Smads then localize to the nucleus and 
cause the transcriptional regulation of target genes (60). Smads can be grouped into three 
categories: 5 receptor-associated Smads (R-Smad-1, 2, 3, 5, and 8), 1 common Smad (Co-
Smad-4), and two inhibitory Smads (I-Smad-6 and 7). R-Smads are sequestered in the 
cytoplasm in the absence of signaling. However, when they are phosphorylated by ALK-5, R-
Smad-2 and 3 associate with Co-Smad4 and translocate into the nucleus (61) to bind to SBE 
(Smad-binding element). Smad-7, on the other hand, works downstream of ALK5 to inhibit 
TGF- signaling. Instead of getting phosphorylated by ALK5, Smad-7 competes with R-
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Smads for ALK-5 binding and recruits Smurf-containing E3 ubiquitinase complexes to 
degrade ALK5 (62, 63). Activated Smad protein complexes bind to DNA weakly, but they 
mostly associate with several other transcription factors to increase DNA affinity. This ability 
to associate with other molecules is responsible for the plethora of effects TGF- has on 
various cells types (64, 65). The Smad-transcription factor complexes then recruit histone 
acetyl transferase (HAT)-coactivators (e.g., CBP/p300) or histone-deacetylase (HDAC) 
corepressors (e.g., Sno/Ski) to activate or repress target genes, respectively (65, 66). These 
signaling effects are summarized in Figure 6. 
 
Figure 6: TGF- signaling from membrane to nucleus. The figure on the left shows the pathway described 
above that involves the phosphorylation of R-Smads, association with co-Smads, nuclear translocation and 
transcriptional activation of genes. The figure on the right shows the inhibition of TGF- signaling by Smad-7 
through competition with R-Smads for ALK5 binding and ALK5 degradation. (Image source: Li et al, Annual. 
Rev. Immunology. 2006) 
 
3.2.1 Effect of TGF- on T cells 
We may state that the overall effect of TGF- on T cells is to bring about suppression of 
immune responses, but this statement needs a lot of clarification into the individual effects 
that TGF- has on various T cell populations. TGF- inhibits T cell proliferation and this is 
done predominantly by targeting IL-2 transcription. TGF-β also inhibits T cell proliferation 
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by inhibiting c-myc, cyclinD2, CDK4 and cyclin E expression in T cell lines and primary 
CD4
+
 T cells (67-69). However, activated T cells lower the expression of TGF- receptor II 
and hence their proliferation is hardly affected by TGF-.  
This effect can be rescued by the addition of IL-10 which increases TGF- receptor II 
expression (70). The inhibition of IL-2 by TGF- is one of the important ways in which TGF-
 prevents autoimmunity as evidenced by the hyperproliferation of thymocytes in TGF- 
deficient mice. TGF- can inhibit the differentiation of CD4+ T cells into either Th1 or Th2 
phenotypes, which under controlled homeostatic conditions is a way to curb the reckless 
differentiation of those cell types that might result in autoimmunity and allergic reactions. 
TGF- blocks Th1 differentiation predominantly by inhibiting T-bet (71) and by blocking 
IFN- production. TGF- can transcriptionally activate IL-10 production which is largely 
anti-inflammatory (72).  
My study focused on TGF--dependent, potentially miRNA-mediated effects on CD8+ T 
cells. As already mentioned, CD8
+
 T cells are our body’s prime fighting front against 
intracellular pathogens (viruses) and tumors through mechanisms already described above. 
TGF- inhibits the CD8+ T cell cytotoxic machinery in a number of ways. TGF- critically 
targets the 5 faced ‘cytotoxic program’ of CD8+ T cells, namely, perforin, granzyme A, 
granzyme B, IFN- and FasL (73). It has been shown conclusively that TGF- directly 
represses the transcription of granzyme B and IFN- through Smad signaling and subsequent 
binding to their respective TGF- responsive ATF1/CREB binding sites (73). The non-direct 
inhibitory effects of TGF- can be attributed in part to the reduction of T-bet expression in 
these cells (74). Reduced T-bet expression in TGF- treated CD8+ T cells also counts for 
reduced IFN- production, though a mutualistic relationship between IFN- and T-bet 
expression makes it hard to determine in which way the repression occurs. 
3.2.2 Tumors and TGF- 
As mentioned above, CD8
+
 T cells with their cytotoxic program are key mediators of our 
adaptive defense against neoplastic growth in our body. Since tumor outgrowth occurs in the 
presence of our immune system, tumors must have evolved several methods of 
immunosuppression and the TGF- mediated mode stands out. In the initial tumor stages, 
TGF- prevents cell proliferation, differentiation, survival, adhesion and metastatic 
progression (75). However, since tumors are genetically unstable, they often overcome or 
evolve beyond the suppressive effects of TGF-. This is done predominantly by turning 
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insensitive towards TGF- signaling through downregulation or mutation of TGF- receptors 
and by harboring defects in the downstream signaling pathway (75). TGF- is secreted by 
various tumors and is often a homeostatic response to the pre-malignant abnormal expansion 
of cells. Once the tumor has dealt with the anti-neoplastic effect of TGF-, it uses the 
cytokine to its advantage. TGF- induces EMT (epithelial to mesenchymal transition), a 
pathological step in tumorigensis which has been demonstrated in breast cancer (76). As 
described earlier, immunosuppression by TGF- is a key weapon in the armory of the tumor. 
In this context, inhibition of the activation receptor NKG2D on NK cell and CD8
+
 T cells is 
significant. The mechanisms behind TGF- mediated NKG2D downregulation has not been 
deduced yet. Our studies have revealed that even when NKG2D mRNA expression is not 
significantly downregulated the protein level expression of NKG2D can be inhibited by TGF-
 in a dose-dependent manner (77). Microarray and qRT-PCR data, however, showed that the 
expression of DAP10 (HCST or hematopoietic cell signal transducer) mRNA was inhibited 
when TGF- was added to NK cells. Being aware that in human cells NKG2D signals 
exclusively through DAP10 and that the hexameric receptor complex on the cell surface 
consists of one NKG2D homodimer and 2 DAP10 homodimers (78, 79), DAP10 was brought 
into focus. All human CD8
+
 T cells constitutively express DAP10 while only activated CD8
+
 
T cells in mice express it. It has been shown that resting NK cells in DAP10 deficient mice 
express little or no NKG2D on the cell surface (80). Based on our preliminary mRNA and 
protein data, we developed the hypothesis that TGF- downregulates NKG2D receptor by 
targeting DAP10. The reasons bringing us towards this conclusion and the difficulties in 
proving it will be explained in the results section.  
3.3 microRNAs (miRNAs)- biogenesis and action.  
My thesis exposes the ability of TGF- to suppress CD8+ T cells through a different, still 
primitively explored mechanism- the induction of immunosuppressive microRNAs 
(miRNAs). While a major part of our genome gets transcribed, only 2% gets translated into 
functional proteins. This very fact leaves us with the task to characterize a whole lot of 
untranslated RNA (non-coding RNA or ncRNA) molecules to fully understand the complex 
physiological and pathological events that take place in our body. So far, among the several 
discovered small ncRNAs like siRNA, piRNA, rasiRNA, tasiRNA, tncRNA, hcRNA, and 
scnRNA, the best studied are the miRNAs. miRNAs were first described in Caenorhabditis 
elegans by Victor Ambros and Gary Ruvkun’s groups in 1993 (81).  
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miRNAs are transcribed by RNA polymerase II or RNA polymerase III into pri-miRNAs 
which are polyadenylated and capped (82-84). pri-miRNAs can be transcribed under the 
control of their own promoter independent of other genes or they can arise after intronic 
cleavage of mRNAs. Co-expression of different miRNAs is quite common (85) The miR-
23a/miR-27a/miR-24-2 cluster (miR-23a cluster) is transcribed by RNA polymerase II by 
binding to its upstream promoter. These pri-miRNAs often undergo sequence editing of 
adenosine to inosine by ADARs (Adenosine Deaminases Acting on RNAs) (86, 87). This 
process greatly influences their further downstream processing in a positive or negative 
manner depending on the sequence of the pri-miRNAs. The pri-miRNA is then cleaved by 
RNAse III enzyme Drosha with the aid of its binding precision partner DGCR8 or Pasha to 
form the pre-miRNA. It has been shown that TGF-β and BMPs induce miRNA maturation by 
regulating the activity of the Drosha-Pasha complex by recruiting RNA helicase DDX5 to 
enhance the processing of certain miRNAs (88).  
Pre-miRNA is then transported out of the nucleus into the cytoplasm by Exportin 5 (XPO5) in 
combination with Ran-GTP (89). The timely uninterrupted transport of pre-miRNAs to the 
cytoplasm is crucial for the prevention of nuclear degradation of the pre-miRNAs. 
Cytoplasmic pre-miRNAs that show a high degree of complementarity in their double 
stranded region are nicked on the 3’ arm by Argonaute 2 (AGO2) which possibly eases strand 
dissociation (90). The RNAse III enzyme Dicer then chops the pre-miRNA to generate 
approximately 22 bp RNA duplexes with 2 nucleotide overhangs at the 3’ end. Two proteins 
namely TRBP (Tar RNA binding protein) and PACT (protein activator of PKR) facilitate the 
binding and functioning of Dicer. Although different from the functional RISC (RNA induced 
silencing complex), the miRNA processing and RISC assembling is mediated by the RISC 
loading complex (RLC) comprising of all the above mentioned proteins (AGO2, Dicer, TRBP 
and PACT). After the formation of the 22 nucleotide duplex, Dicer, TRBP and PACT 
dissociate from the complex. The duplex then unwinds with the help of several helicases and 
the strand with its 5’ end at the less stable base pair end of the duplex is loaded onto the RISC 
complex which includes the AGO2 protein. The events from pri-miRNA transcription to 
mature miRNA/RISC complex formation are summarized in Figure 7. 
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Figure 7: miRNA processing pathway. Mature miRNA synthesis via processing of pri- and pre-forms by the 
various protein complexes are depicted. (Image source: Julia Winter, Sven Diederichs et al., Nature Cell Biology  
March 2009) 
 
RISC is a generic term for miRNA/siRNA containing protein complexes that are capable of 
targeting mRNAs to effect translational inhibition. Common feature of all RISC complexes 
are the presence of an Argonaute family protein which binds and places the regulatory short 
RNA (or guide strand) in a conformation that enables base pairing with target mRNAs. 
Several other proteins may be present alongside Argonaute that can complement its function. 
The guide strand binds with its 5’ end (usually 2nd -8th bases) to target mRNAs by Watson-
Crick base pairing (91, 92). The consequence of this base pairing is translational repression of 
the mRNA. Only at near perfect complementarity does the slicing activity of Argonaute 
(AGO2 in humans) cut the mRNA to destroy the reading frame (93). However, such extensive 
base pairing is uncommon in the case of mammalian miRNAs and more often miRNAs pair 
with their 2
nd
 -7
th
 bases to the 3’UTR of an mRNA (referred as the ‘seed region’) to initiate 
translational repression (94). Several modes of action have been described to explain how 
translational repression is carried out by miRNAs. This has been extensively reviewed in Cell 
(95). It has been shown that for miRNAs to inhibit translation, mRNAs need to have an intact 
7-methylguanylate (m
7
G) cap and a poly A tail (96). miRNAs can inhibit translation initiation 
by utilizing the m
7
G binding motif of Argonaute proteins (97). Evidence for a possible 
interference during translation comes from the co-sedimentation of miRNAs with 
polyribosomes (98). 
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3.3.1 miRNA quantification, profiling and functional characterization 
In order to understand the involvement of miRNAs in various biochemical processes and 
pathways it is necessary to quantify their expression. Since they are not translated, miRNAs 
are quantified on RNA level. Advanced biochemical methods enable the isolation of intact 
miRNAs from a wide variety of sources like, formalin fixed paraffin embedded (FFPE) 
sections, fresh tissues, tumor cell lines, immune cells, whole blood, serum and several other 
body fluids. miRNA profiles from several body fluids have been  identified as potential 
biomarkers for diseases (99-101). Most miRNA isolation procedures are similar to established 
RNA isolation methods but include an additional small RNA enrichment process involving 
silica columns or stringent precipitation steps. miRNAs have been found to be extremely 
stable even when isolated from FFPE sections, when compared to mRNAs, making them 
attractive tools in clinical studies. 3 approaches are widely used for miRNA quantifications, 
1) Microarrays (miRNA arrays) 
2) Quantitative real time PCR (qRT-PCR) 
3) Next generation sequencing (NGS) or Deep sequencing or high throughput 
sequencing. 
3.3.1.1 miRNA arrays  
miRNA arrays or miRNA microarrays were one of the first strategies to quantify and profile 
miRNA expression. Although several variations exist, the backbone of the technique is the 
hybridization of miRNAs onto probes immobilized on array chips. miRNAs in samples may 
be fluorescently labeled to enable detection. Even here, LNA probes can be used to solve 
hybridization temperature variability. One major advantage or arrays is that one can 
immobilize the same probe to different regions of the array and get replicate hybridization 
signals which enable statistical evaluation of binding intensity and minimize error rates. 
However, a certain sequence specific bias towards hybridization of the fluorophores and the 
interference by other cellular RNAs are drawbacks.  Some of the commercially available 
miRNA microarray platforms are (or, in some cases, were) Geniom Biochip miRNA (febit 
GmbH now CBC, GmbH), GeneChip miRNA array (Affymetrix), GenoExplorer 
(Genosensor), MicroRNA microarray (Agilent), miRCURY LNA microRNA array (Exiqon), 
NCode miRNA array (Invitrogen), Nanostring OneArray  (Phalanx Biotech), Sentrix array 
matrix and BeadChips (Illumina), μParaFlo biochip array (LC Biosciences) and miRXplore 
microarrays (Miltenyi biotech) (102).  
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3.3.1.2 qRT-PCR 
This approach converts miRNAs to cDNA followed by qPCR amplification and detection. It 
can be easily established in laboratories with qPCR expertise. High throughput quantification 
of up to several hundreds of miRNAs using qRT-PCR is possible through the employment of 
multi well plates and auto micro sampling techniques. However, massively parallel miRNA 
quantifications are hindered by the fact that miRNAs vary in their hybridization temperatures. 
Recently, the use of Locked Nucleic Acid (LNA) probes has made substantial progress in 
improving miRNA hybridizations. 2 commonly used strategies of miRNA qRT-PCR are 
shown in Figure 8. 
 
 
Figure 8. Schemes of miRNA qRT-PCR quantification. The top panel shows the use of stem loop primers to 
generate miRNA cDNA which is followed by qPCR and TaqMan probe mediated detection of amplification. 
The bottom panel shows the approach used to quantify miRNAs in my doctoral thesis. miRNAs are elongated by 
adding a poly-A tail (polyadenylation). Then an anchored oligo dT primer with a known sequence is used to 
generate the cDNA. Using the cDNA as template, a miRNA specific primer is used to amplify and quantify the 
respective miRNAs using qPCR. (Image source: Pritchard et al. Nature Reviews Genetics, 2012) 
 
3.3.1.3 Deep Sequencing or Next Generation sequencing 
NGS has emerged a powerful tool for miRNA profiling with extremely high throughput and 
massively parallel sequencing capabilities. Although this is the costliest of the 3 techniques 
mentioned here, recent advancements in instrumentation and ability to include several 
samples into a single sequencing reaction have made it more affordable as a routine profiling 
approach. The major advantage of deep sequencing is the fact that alongside known miRNAs, 
novel miRNAs can be discovered. miRNAs are converted to cDNA and are cloned and 
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expanded to create a library which are then sequenced. Prior to sequencing, cDNA from 
unique samples can be bar-coded using known adaptor sequences which can be identified and 
sorted after sequencing. This enables several samples to be mixed and sequenced together. In 
addition to the earlier mentioned cost effectiveness, this strategy also minimized sequencing 
errors and biases across different sequencing runs. NGS can successfully resolve miRNAs 
that differ by even one nucleotide. In my study, we were able to distinguish human miR-23a 
(AUCACAUUGCCAGGGAUUUCC) and miR-23b (AUCACAUUGCCAGGGAUUACC). 
Drawbacks of NGS include sequencing errors (which can be critical considering the short 
length of miRNAs) and the relatively cumbersome bioinformatic analysis and data mining 
from the sequenced reads which often requires help from statisticians. Some of the available 
sequencers are (Ion Torrent (Life Technologies), Genome Sequencer 20 (454 Life Sciences), 
MiSeq, Solexa and HiSeq 2000 (Illumina), SOLiD (Life Technologies) and GS Junior 454 
(Roche) (102-104). 
 
3.3.1.4 Tools for miRNA target prediction 
Once miRNAs are quantified or profiled, the next step towards determination of their function 
is to identify mRNAs that they can potentially target. As described earlier, the imperfect 
complementarity of miRNA-mRNA base pairing enables literally thousands of mRNAs to be 
potentially targeted. It has been predicted that a single miRNA can target over 300 mRNAs in 
a cell. There are several tools available at present to predict mRNA-miRNA interactions. 
These tools use several parameter to make such predictions, which include base pairing 
between the 3' UTR of mRNAs and the miRNA seed region, nucleotide composition of 
flanking sequence, thermodynamic stability or free energy of miRNA binding, evolutionary 
conservation of binding sites, sterical accessibility of the miRNA towards mRNA secondary 
structures as well as expression of particular genes in the host, cell or tissue type (105). Some 
of the common miRNA target prediction tools and their links are listed in Table 1. 
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3.3.1.5  Tools for miRNA functional analysis 
No matter how strong or how probable a predicted miRNA-mRNA interaction may be, there 
are several other unpredictable factors that determine whether the miRNA is able to inhibit 
mRNA translation in a physiological setting. In order to establish that an interaction is indeed 
possible within a live cell, luciferase reporter gene assays are commonly used. Here, miRNA-
interactable RNA regions of genes (usually the complete or part of the 3’UTR of suspected 
target mRNAs) are cloned downstream of luciferase (firefly luciferase from Photinus pyralis). 
These reporter constructs are then transfected into cells that express the miRNA. Relevant 
controls that either lacks the 3’UTR of the target gene or that contain 3’UTRs with mutations 
within the miRNA interacting region are also transfected in parallel. Reduced reporter activity 
in wild type constructs when compared to the mutated construct indicates miRNA 
interference in the cloned regions. To determine whether a particular miRNA is interfering 
with the reporter, co-transfection of reporter constructs along with specific miRNA inhibitors 
(antisense 2 ′ -O-methyl − modified oligoribonucleotides or antagomirs) or miRNA mimics 
are used. Once a specific miRNA-mRNA interaction is functionally determined, antagomirs 
and mimics can be used to further understand the control of the miRNA over the expression 
of that particular gene or its signaling pathways in relevant cells. miRNA mimics are double 
stranded and mimic the miRNA duplex, hence their transient expression is only suitable only 
for short term cellular assays. For long term in vitro and in vivo assays, DNA plasmids that 
can continuously generate the miRNA under endogenous, viral or tissue specific promoters 
are used (106). 
3.3.2 miRNAs in cancer 
Several miRNAs are deregulated in almost all cancers. Defects in miRNA processing 
machinery have been reported to play a role in the prognosis of cancers. In a significant 
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cohort of non-small cell lung cancer patients, the expression of dicer was shown to be 
downregulated which correlated with poor operative survival (107). In general, miRNAs that 
target tumor suppressors can drive tumorigenesis and those that target oncogenes and growth 
factors may be suppressive to the tumor (108). let-7 miRNA acts as a tumor suppressor by 
inhibiting the expression of Ras and mutations in let-7 have been shown to control cell 
proliferation in human cell lines and cancers (109). Nearly 50% of human miRNAs have been 
shown to lie within fragile sites of our genome (110). These fragile sites are often the first to 
take the hit of agents that cause genomic instability. Clustered miRNAs miR-15a and miR-16-
1, which can target the anti-apoptotic gene Bcl-2, lie within a genomic region that is often 
deleted in B-CLL (B cell chronic lymphocytic leukemia), prostate cancer and multiple 
myeloma. These 2 miRNAs have thus been implicated as a tumor suppressors as their 
suppression (or deletion) increases the anti-apoptotic gene Bcl-2 which then drives 
tumorigenesis (111, 112).  Similarly, miR-143 and miR-145 act as tumor suppressors and are 
downregulated in colorectal and breast cancers (113, 114). miR-155 has been implicated as a 
promoter in several lymphomas and breast cancers while miR-21 plays the role of an anti-
apoptotic factor driving glioblastomas (113, 115, 116). One well recognized oncogenic 
miRNA cluster, the miR-17-92 cluster which includes miR-17-5p, miR-18a, miR-19a, miR-
19b, miR-20a, miR-92-1 is induced by oncogenic Myc and is upregulated in B cell 
lymphomas where the members function co-operatively as oncogenes (117).  
3.3.2.1 As cancer markers 
Since miRNA expression is closely related to genomic instability, miRNA profiles are 
potential aids to predict the presence, type and stage of several cancers. Cytosolic miRNAs 
are packaged into exosomes and expelled into circulation. Circulating miRNAs within blood 
are a promising and minimally invasive marker for cancer diagnosis (118, 119). In blood and 
tissue from colorectal cancer patients, the expression of miR-23a was shown to increase along 
with disease progression suggestive of its diagnostic potential (120). Our group has shown the 
predictive power of miRNA profiles in whole blood from ovarian cancer patients where it was 
possible to discriminate healthy and serous subtype ovarian cancer samples with an accuracy 
of > 85% (99). However poor consensus among various studies still limits the full predictive 
potential of miRNA profiles. 
3.3.2.2 As therapeutic targets 
All miRNAs that act as tumor suppressors or tumor promoters are potential candidates as 
cancer therapeutic targets. However the critical hurdle to cross is the delivery of miRNA 
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modulators into the patients’ cancer cells. Viral based miRNA delivery methods are the most 
effective way to transfer miRNAs in vitro but the immunogenicity of such a technique hinders 
its application in patients. However, in immunotherapy, this technique holds untapped 
potential. Nano technology has successfully delivered miRNAs and inhibitors to cancer cell 
lines. Lipid nanocapsule-locked nucleic acid complexes targeting miR-21 were able to 
sensitize glioblastoma cells to irradiation (121). A neutral lipid emulsion containing either 
miR-34a or let-7b significantly reduced lung tumor growth in mice (122). Much of the 
research on miRNA in vivo delivery systems focuses on minimizing toxicity. However the 
field of miRNAs use in cancer therapy is definitely gaining pace towards translational 
research.  
3.3.3 Scope of my PhD thesis 
The major part of my study that is elaborated describes the profiling of miRNA changes that 
occur in human CD8
+
 T cells upon initiation or blocking of TGF- signaling, which lead to 
the identification of the miR-23a cluster. Reporter gene assays and functional assays showed 
that this cluster can inhibit LAMP-1 and IFN- as well as repress antigen specific cytotoxicity 
in CD8
+
 T cells. These findings reveal a previously unidentified mechanism by which TGF- 
inhibits CD8
+
 T cell effector functions. On a broader perspective, immune regulatory 
miRNAs are exciting targets in clinical research. Whether inhibition of the miR-23a cluster 
can augment T cell responses against tumors and other infections has to be tested in suitable 
animal models. I also studied the mechanism of NKG2D downregulation in NK cells upon 
TGF- treatment. While we initially suspected an involvement of miRNAs, this could not be 
confirmed. Instead, we arrived at a hypothesis suggesting that TGF- dependent 
downregulation of the signaling counterpart of NKG2D, namely DAP10, could prevent the 
assembly of a complete NKG2D receptor complex and thus reduce NKG2D surface levels. 
This hypothesis is based on a number of experiments which showed that DAP10 mRNA is 
downregulated by TGF-. Further, I contributed to various other studies which were 
published and which are summarized towards the end of my thesis. 
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4 Materials and methods 
4.1 Isolation of PBMCs 
Blood was drawn from healthy donors and mixed with acid citrate dextrose solution to a final 
concentration of 10% to prevent clotting. 50 ml of citrated-blood was then diluted with 90 ml 
PBS. 15 ml Biocoll lymphocyte separation medium was added to centrifugation tubes (50 ml). 
The citrated-blood-PBS mixture was gently layered over the Biocoll. The tube was then 
centrifuged for 20 minutes at 600 rpm (in a centrifuge from Jouan/Thermo Electron GmbH, 
63303 Dreieich, Germany) with very low acceleration and deceleration at room temperature. 
5 ml fluid was removed from the top to remove the platelets. The tube was again centrifuged 
for another 30 minutes at 1400 rpm with very low acceleration and deceleration at room 
temperature. PBMCs that accumulated at the interphase of Biocoll and serum were harvested 
into another tube and were washed twice with PBS. 
4.1.1 Purification of CD8+ T cells and NK cells from PBMCs 
Untouched CD8
+
 T cells were purified from PBMCs using the human CD8
+
 T cell isolation 
kit and NK cells were purified using human NK cell isolation kit (Miltenyi Biotec) on LS 
columns as instructed by the manufacturer. Cells and buffers were maintained at 4°C 
throughout the purification procedure. The following volumes were used for 10
8
 PBMCs: 
PBMCs were harvested by centrifuging them at 300 g for 10 minutes. Subsequently, they 
were resuspended in 400 µl of MACS buffer (PBS pH 7.2 with 0.5% BSA and 2 mM EDTA). 
100 µl of CD8
+ 
T cell Biotin-Antibody Cocktail was added, mixed well and incubated for 5 
minutes. 300 µl of MACS buffer was added followed by 200 µl CD8
+
 T cell (or NK cell) 
Microbead Cocktail and the mixture was incubated for 10 minutes. Cells were diluted with 10 
ml of MACS buffer, centrifuged at 300 g for 10 minutes and resuspended in 500 µl MACS 
buffer.   
A MACS LS column was mounted on a magnetic holder and was rinsed using 3 ml of MACS 
buffer. The cell suspension was added to the column and the eluate, which contained 
untouched CD8
+
 T cells (or NK cells), was collected. The column was further rinsed 3 times 
using 3 ml of MACS buffer.  
The purity of the isolated CD8
+
 T cells and NK cells were determined using flow cytometry. 
This method yielded consistently between 85% - 95% CD8
+
 T cells and NK cells (Figure 9). 
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Figure 9. Purity of CD8
+
 T cells enriched using CD8
+
 T cell isolation kit. PBMCs (left) and purified CD8
+
 T 
cells (right) were stained with CD8 FITC and CD3 PE-Cy5 antibodies (Immunotools) and were analyzed using a 
flow cytometer. 
4.1.2 Isolation of murine CD8+ T cells 
Murine CD8
+
 T cells were isolated, activated and treated with TGF- by Katerina Andreev 
under the supervision of Prof. Dr. Susetta Finotto. In brief, spleens from Balb/cJ hCD2-
∆kTRII (123) and Balb/cJ wild-type mice were passed through a cell strainer and red cells 
were lysed by hypotonic solution as previously described (124). CD8
+
 T cells were purified 
from splenocytes using magnetic anti-mouse CD8 microbeads (Miltenyi Biotech, Bergisch 
Gladbach, Germany), according to the manufacturer´s instructions. Using FITC-conjugated 
anti-mouse CD8 antibody (clone 53-6.7, BD Biosciences, Heidelberg, Germany), the purity of 
the isolated CD8
+
 T cells was confirmed to be between 88% and 93%.   
4.2 Cell culture 
4.2.1 PBMCs 
PBMCs were maintained in RPMI 1640 with 10% fetal bovine serum (FBS), 100 units/ml 
penicillin, 0.1 mg/ml streptomycin and 50 µM sodium pyruvate. 
4.2.2 CD8+ T cells isolated from PBMCs 
Human CD8
+
 T cells used for miRXplore
TM
 arrays and deep sequencing were cultured in X-
VIVO
TM
 15 medium (Lonza, Basel, Switzerland). For functional experiments, CD8
+
 T cells 
were cultured in RPMI 1640 with 10% FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin 
and 50 µM sodium pyruvate. 
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4.2.3 Antigen specific CD8+ T cells 
Melan-A specific and STEAP specific CD8
+ 
T cells were cultured in CellGro DC Medium 
(CellGenix, Freiburg, Germany) supplemented with 5 % human serum (Biochrom), 30 IU/ml 
IL-2 (Peprotech) and 5 ng/ml IL-15 (Peprotech). 
4.2.4 Cell lines 
HEK293T cells were cultured in DMEM (high glucose), 10% FBS, 100 units/ml penicillin, 
0.1 mg/ml streptomycin and 50 µM sodium pyruvate. FM55 cells were cultured in RPMI 
1640 with the same supplements. These adherent cell lines were grown until they were 80% 
confluent and were thereafter split into thinner densities after detaching them using 
Trypsin/EDTA solution (PAA). NKL cells were cultured in the same medium used for FM55 
additionally supplemented with 20 IU/ml rh-IL-2 (Catalog no. 200-02, Peprotech) while NK-
92 cells were cultured in IMDM medium (+25mM HEPES) (PAA) supplemented with FBS 
(10% final), horse serum (10% final), 100 units/ml penicillin, 0.1 mg/ml streptomycin, 2 mM 
L-glutamine, 50 µM sodium pyruvate and 100 IU/ml rh-IL-2 (Peprotech). 
4.2.5 Manual cell counting 
Cells were washed once with PBS. 20 µl of cell suspension was diluted with 20 µl of 0.1% 
Trypan blue solution and the cells were counted using a Neubauer counting chamber. Total 
cell numbers were determined as follows: 
Total cell count =
no. cells in 4 quadrants x 2 x 10000 x total volume of cell suspension
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4.3 In vitro activation of CD8+ T cells 
Human CD8
+
 T cells were activated using the T cell activation/expansion kit (Miltenyi 
Biotec). Anti-biotin MACSiBead particles were coupled to anti-CD2, anti-CD3, and anti-
CD28 antibodies as follows.   
100 µl MACSiBead particles solution was mixed with 20µl each of anti-CD2, anti-CD3, and 
anti-CD28 antibodies. Then 40 µl of MACS buffer was added. The resulting mixture had a 
concentration of 10
5
 beads /µl and was incubated at 4°C for at least 4 h with slight agitation. 
CD8
+
 T cells were then stimulated with this mixture at a 1:2 bead/T cell ratio.  
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4.4 miRNA microarrays 
Human CD8
+
 T cells were isolated as stated above from 5 different donors and were activated 
with activation/expansion beads for 24 h. Then, the cells were either left untreated (control) or 
treated with TGF-1 (5 ng/ml) (Peprotech) or the TGF- receptor 1 kinase inhibitor SD-208 
(1 µM) (Tocris, Bristol, UK) (125). After 15 min, aliquots were drawn to check for 
phosphorylation of SMAD2/3. 24 h later, the cells were centrifuged at 400 g for 10 minutes, 
snap-frozen in liquid N2 (-195°C) and shipped to Miltenyi Biotec. Cells belonging to the same 
group were pooled from each donor and the total RNA was isolated and purified (Trizol 
reagent). Bioactivity of TGF- was assessed via SMAD2/3 phosphorylation at 15 min and via 
downregulation of NKG2D after 24 h (126). RNA from the control and SD-208 groups were 
fluorescently labeled with Hy3 and the TGF- group was labeled with Hy5. 1.5 µg of the 
fluorescently labeled total RNA was then mixed in pairs (TGF- with control and TGF- with 
SD-208 group) and hybridized overnight to miRXplore
TM
 microarrays using the a-Hyb
TM
 
hybridization station. Fluorescence signals were detected using a laser scanner (Agilent). For 
each spot of the microarray images, mean signal and mean local background intensities were 
obtained using the ImaGene
R
 software (Biodiscovery). Normalized mean Hy5/Hy3 ratio of 4 
replicates of each miRNA was calculated using miRXplorer software (Miltenyi Biotec). 
4.5 Generation of small RNA libraries from CD8+ T cells 
CD8
+
 T cells from 5 different donors were treated in exactly the same way as for the miRNA 
arrays. Small RNA libraries were generated by Vertis Biotechnology AG (Freising-
Weihenstephan, Germany) as described earlier (127). Briefly, RNA was isolated and resolved 
on a denaturing 12.5% polyacrylamide gel. RNA molecules that were 15-30 bases long were 
then concentrated by ethanol precipitation. RNAs were then polyadenylated and 5’ adapter 
sequences were ligated onto them. The 5’ adapter sequence used for each group was  
5'-GCCTCCCTCGCGCCATCAGCTNNNNGACCTTGGCTGTCACTCA-3', where NNNN 
represents a ‘bar code’ sequence for the 3 groups (GCTC for RNA from the TGF-1-treated 
group, CCGA for the SD-208-treated group and GTAT for the control group).  
Then, cDNA synthesis was performed using an oligo(dT)-linker primer and M-MLV-RNase 
H- reverse transcriptase. cDNAs were  PCR-amplified  in  22 cycles.  The resulting 120 - 135 
bp amplification products were confirmed by polyacrylamide gel electrophoresis (PAGE). 
cDNA pools were mixed in equal amounts, gel fractionated and electro-eluted  from  6%  
PAA-gels.  After isolation  with  Nucleospin Extract  II  (Macherey  and  Nagel)  cDNA  
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pools  were  dissolved  in  5 mM Tris/HCl, pH 8.5 at a concentration of 10 ng/µl and used in  
single-molecule  sequencing.  Massively parallel sequencing was performed by 454 Life 
Sciences (Branford, USA) using the Genome Sequencer 20 system.  
4.5.1 Analysis of deep sequencing results 
By identifying the ‘bar code’, sequences from control, TGF- and SD-208 groups were 
separately filed in ‘’.xls format. The following steps were then performed using Pearl scripts 
written by Jiayun Zhu (Research Group, Prof. Dr. Gunter Meister), that were modified 
according to the nature and number of reads in each group. The 5’ adapter sequence and the 
polyA tail were removed. The resulting 25 base sequences were screened for unrecognizable 
bases (sequencing errors, designated as N) and these bases were removed. The sequences 
were then arranged in descending order according to base count. In the next steps 2 groups 
were combined in one file, side-by-side, for comparison. We combined the control and the 
TGF- group and the SD-208 and the TGF- group. The number of same reads was then 
counted for each group and was assigned to each read. The sequences were then arranged in 
descending order according to read counts. Since 454 sequencing results typically show 
abnormal ‘A’ inserts within reads, we eliminated all ‘A’s in all the reads, however one row 
with the parental sequence was maintained during the analysis. Then the sequences were 
annotated by comparing them against all miRNAs in the miRBase (www.mirbase.org). Usage 
of a non-stringent comparison and possibility of sequencing errors, the annotated sequences 
were further cross-checked manually, one at a time, for abnormal base repeats (e.g. CCC 
could be sequenced as CC or CCCC), rather short sequenced due to the removal of ‘A’s, as 
well as for unannotated sequences that were left out due to shortened reads. After this step, 
the number of reads for each miRNA in the various groups was determined. To facilitate 
comparison between the different data sets, miRNA counts were normalized to 10
4
 reads and 
ratios were calculated for each individual miRNA by dividing the number of normalized reads 
in the TGF- treated group by the number of reads in either the control or the SD-208 treated 
group.  
4.6 NK cell mRNA microarrays 
(performed by Yvonne Dombrowski) 
NK cells were isolated from 6 healthy donors and were treated with 5 ng/ml TGF- or left 
untreated for 24 h. Cells from each donor for the same treatment were pooled at 4°C, snap 
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frozen in liquid N2 and were shipped to Miltenyi Biotec. RNA was isolated and quality 
controlled. RNA from the control group was fluorescently labeled with Cy3 and the TGF- 
group was labeled with Cy5. 825 ng of the corresponding Cy3- and Cy5-labeled fragmented 
cRNA were combined and hybridized overnight (17 h, 65 °C) to Agilent Whole Human 
Genome Oligo Microarrays. Fluorescence signals were detected by the DNA microarray 
scanner (Agilent Technologies) and the corresponding Cy5/Cy3 fluorescence ratios were 
calculated to indicate gene regulations. 
4.7 Identification of new miRNAs 
Unannotated miRNAs with about 50 or more read counts were aligned against the human 
genome. The chromosomal location of sequences that showed 100% homology were then 
determined and 40-50 bases either upstream or downstream were retrieved. This stretch of 
RNA was then folded using the RNAfold WebServer, Institute for Theoretical Chemistry, 
University of Vienna (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).  
4.8 Quantification of miRNAs by qRT-PCR 
Isolation of miRNAs for qRT-PCR was optimized by comparing various available kits in the 
market. Best results were obtained when the RNA was isolated and the miRNA fraction was 
enriched using the Absolutely RNA/miRNA Kit (Agilent Technologies, Böblingen, 
Germany). 10
6 
cells were used per isolation and the miRNAs were eluted using 50 µl of 
RNase-free water. The isolated miRNAs were then 3’-poly-adenylated using the E. coli 
polyadenylase enzyme (Agilent Technologies). 
 
 
 
Several available reverse transcriptases were tested in parallel for their efficiency to reverse 
transcribe the poly-adenylated miRNAs. Affinityscript reverse transcriptase (Agilent 
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Technologies) proved to be the best and thus cDNA synthesis was henceforth performed with 
the High specificity miRNA First Strand Synthesis Kit (Agilent Technologies) with an 
anchored oligo-dT primer with a universal recognition sequence (URT-primer).  
 
 
 
miRNA expression was quantified using ABsolute
TM
 QPCR SYBR Low ROX mix (Thermo 
Scientific) together with miRNA specific forward primers and a URT  specific primer. Our 
protocol was adapted from a previous study (128). 
 
 
The resulting CT values for the respective miRNAs were then quantified by the CT method 
using U6 ribosomal RNA as internal control. For murine CD8
+
 T cells, the same miRNA-
specific primers could be used. Here, however, SNORD70 was chosen as internal control. 
4.9 Quantification of mRNAs by qRT-PCR 
Up to 5 x 10
6
 cells were lysed using 500µl of peqGOLD TriFast (Peqlab Biotechnology) and 
total RNA was isolated following the manufacturer’s instructions. RNA purity (A260/A280) 
and concentration were determined using a spectrophotometer. In short, 2 µl of the total RNA 
fraction was diluted in 198µl (dd) H2O; the absorbance was measured at 260 and 280 nm 
against (dd) H2O control. The concentration was calculated using the formula:  
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C [μg / ml] = OD 260 nm  x dilution factor x 40. The  purity  of  the  isolated  RNA  was  
estimated  by  dividing  the  value  obtained  for  the absorbance  at  260  nm  by  the  
absorbance  measured  at  280  nm.  Ratio of OD 260 nm /OD 280 nm  close to 1.8 indicated 
good purity. 0.5 µg of total RNA was reverse transcribed into cDNA using iScript
TM
 synthesis 
kit (Biorad). 
 
mRNA expression was quantified by SybrGreen based real time PCR using ABsolute Blue 
qPCR low ROX mix (Thermo Scientific) on an ABI 7500 Fast thermocycler (Applied 
Biosystems, Life Technologies). 
 
 
4.10 PCR amplifications 
Amplification of 3’UTRs for cloning reporter constructs was performed using Crimson 
longAmp Polymerase Kit (NEB) on CD8
+
 T cell cDNA.   
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4.11 Transfection of CD8+ T cells 
Our laboratory is equipped to safety level S1 which does not allow us to perform viral 
transductions. Primary immune cells are very difficult to transfect with non-viral methods. 
Since this study routinely involved the modulation of miRNA levels in primary CD8
+
 T cells, 
we decided to optimize a non-viral and relatively homogenous method of transfecting these 
cells with least variability between successive transfections. We tested several commercially 
available transfection reagents in parallel using FAM labeled anti-miRNA control (Ambion, 
Life Technologies) for their efficiency in transfecting primary CD8
+
 T cells. 
Based on our observations (Table 2), we decided to nucleofect CD8
+
 T cells using the T cell 
nucleofection reagent. Although high transfection rates were obtained using TRANS-IT TKO, 
the reagent was highly toxic to CD8
+
 T cells. Briefly, 2-5x10
6
 CD8
+
 T cells were washed with 
PBS and MACS buffer (2 mM EDTA and 0.5% BSA in PBS; pH 7.2) before being 
nucleofected either with 1 µg of plasmid DNA or with 300 nM miRNA mimics, antagomirs or 
control RNA. Immediately after nucleofection [performed with Amaxa
®
´s Human T cell 
Nucleofector
®
 kit (VPA-1002, Lonza) and program U-014], the cells were transferred into 
fresh, warm medium (37°C). 
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Table 2. Efficiency of various transfection reagents while transfecting CD8
+
 T cells. Purified CD8
+
 T cells 
were transfected with FAM- anti-miRNA negative control RNA using the above listed transfection reagents 
following instructions provided by the respective suppliers. Untransfected cells served as control. The respective 
percentages of FAM positive cells were determined by flow cytometry and are indicated in the above table. 
4.12 Antagomirs and mimics 
Antagomirs are synthetic anti-sense 2’-O-Methyl RNA oligos which are perfectly 
complementary to the target miRNA which they inhibit.  
Antagomir for miR-23a (ant-23a): r[2'-OMe](GGAAAUCCCUGGCAAUGUGAUU)dT 
Antagomir for miR-27a (ant-27a): r[2'-OMe](GCGGAACUUAGCCACUGUGAAU)dT 
Antagomir for miR-24 (ant-24): r[2'-OMe](CUGUUCCUGCUGAACUGAGCCAU)dT 
Antagomir for miR-9 (ant-9): r[2'-OMe](UCAUACAGCUAGAUAACCAAAGA)dT 
Since deep sequencing and qRT-PCR both showed that miR-9 was not expressed in CD8
+
 T 
cells, antagomirs against this miRNA served as control in our experiments. miRNA mimics 
and control RNA were obtained from commercial providers: mimic-23a: Syn-hsa-miR-23a 
miScript miRNA Mimic (Cat.no:MSY0000078), mimic-27a: Syn-hsa-miR-27a miScript 
miRNA Mimic (Cat.no:MSY0000084, Qiagen, Hilden, Germany), mimic-24: hsa-miR-24 
miRIDIAN Mimic (Cat.no: C-300496-05-0005, Dharmacon RNAi Technologies, Thermo 
Scientific) and control RNA: All stars negative control RNA (Cat.no. 1027280, Qiagen). 
The efficacy of the antagomirs and mimics to deregulate miR-23a cluster was tested and is 
shown in Figure 10. 
 
 
Figure 10. Efficacy of antagomirs and mimics in CD8
+
 T cells after nucleofection. (A) CD8
+
 T cells were 
nucleofected with an antagomir cocktail (antagomirs against miR-23a, miR-27a and miR-24, 100 nM each) or 
without any antagomirs and the expression of these miRNAs was quantified 24 h later by qRT-PCR. miR-20 and 
miR-150 were also quantified to control for off-target effects. U6 snRNA was used as internal control. 
Expression values were normalized to the mock-nucleofected control. (B) The expression of miR-23a in CD8
+
 T 
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cells was monitored over 5 days after nucleofection with an antagomir against miR-23a. For functional assays in 
this study, the maximum duration of experiments involving antagomirs was 60 h after nucleofection. (C) CD8
+
 T 
cells were either mock-transfected or nucleofected with a cocktail of miRNA mimics (containing 100 nM each 
of mimics for miRNA-23a, miR-27a and miR-24) and the expression of these miRNAs was quantified 24h later 
by qRT-PCR. U6 snRNA was used as internal control. Further, miR-20 and miR-150 were quantified to control 
for off-target effects. The displayed expression values were normalized to the group nucleofected without any 
mimics. p-values were determined using Student’s t-test (ns- not significant, * p<0.05, ** p<0.01, *** p<0.001). 
4.13 Priming and generation of Melan-A- and STEAP-specific T cells 
The detailed priming protocol has been previously described (129) and was performed at the 
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Children's 
Hospital, University of Würzburg Medical School under the supervision of Dr. Matthias 
Wölfl. Briefly, DCs were generated from plastic-adherent monocytes. After 72 h of culture in 
GM-CSF/IL-4-containing DC medium (Cellgenix, Freiburg, Germany), DCs were matured in 
medium containing 100 ng/ml IL-4 (Peprotech), 800 IU/ml GM-CSF (Peprotech), 10 ng/ml 
LPS, and 100 U/ml IFN- (Peprotech) plus Melan-A-peptide (26-35(A27L)) (ELAGIGILTV, 
2.5 g/ml) (JPT, Berlin, Germany). After 16 h, DCs were irradiated (30 Gy) and co-incubated 
with CD45RO
-
, CD57
-
 naïve CD8
+
 T cells at a 1:4 ratio in medium containing 5% AB serum 
and 10 ng/ml IL-21 (Peprotech). Fresh medium, IL-7 (Peprotech), and IL-15 (Peprotech) were 
added on days 3, 5, and 7 of culture, before evaluation on day 10-12. The percentage of 
Melan-A specific T cells was determined by MHC-multimer staining (Immudex, 
Copenhagen, Denmark). When further purification was required, antigen-specific T cells were 
stained with appropriate Dextramer-APC conjugates (Immudex) and enriched using magnetic 
anti-APC Beads (Miltenyi) according to the manufacturer’s instructions.  
To obtain STEAP-specific T cell clones, cells from an HLA-A02:01
+
 donor were primed and 
expanded similar to Melan-A-specific T cells, using the STEAP peptide MLAVFLPIV 
(292.2L) (JPT, Berlin, Germany). The cells were then purified using a Dextramer-APC 
conjugate and clones were obtained via limiting dilution: To this aim, 0.3-3 Dextramer 
enriched T cells per well were seeded in 96 well plates and cultured together with 200,000 
feeder cells/well (PBMCs from three different, HLA- mismatched donors at a 1:1:1 ratio) and 
30 ng/ml soluble OKT3 (Orthoclone
TM
, Janssen-Cilag, Neuss, Germany) in CellGro DC 
Medium (CellGenix, Freiburg, Germany) supplemented with 5 % human serum (Biochrom), 
30 IU/ml IL-2 (Peprotech) and 5 ng/ml IL-15 (Peprotech). This medium was also used for 
subsequent culture. After 14 days, specific T cell clones were identified by dextramer staining 
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and restimulated on irradiated feeder cells with OKT3. Cells were then used for experiments 
or stored at -185°C. When thawed, cells were restimulated on irradiated feeder cells with 
OKT3. Experiments were done at least 10 days after restimulation. In order to restimulate the 
antigen specific T cells using monocytes pulsed with peptides, CD14 positive cells were 
purified from PBMCs using magnetic beads (Miltenyi Biotec). These cells were then fed with 
100 ng/ml IL-4 (Peprotech), 800 IU/ml GM-CSF (Peprotech) and the respective peptide (1 
g/ml) for 24 h before they were mixed with T cells. 
4.14 Reporter vectors and cloning 
miRNA binding to the 3’ UTR of putative targets was analyzed with a dual reporter plasmid 
pMIR-RL (Figure 11) encoding both Renilla reniformis and Photinus pyralis (firefly) 
luciferase (130). 
Briefly, Renilla reniformis luciferase is constitutively expressed under the SV-40 promoter 
and is used to normalize for transfection efficiency. Transcription of firefly (Photinus pyralis) 
luciferase is driven by the weaker HSV-TK promoter. To render this signal susceptible to 
inhibition by miRNAs, the 3’UTR of the gene of interest was fused to the firefly luciferase 
sequence.  
For amplification of the 3’UTRs of LAMP1 and IFN-, cDNA from CD8+ T cells was used as 
template and amplified with the following primers (containing restriction sites for either Spe1 
or Pme1):  
LAMP1 3’UTR forward: CGCTACTAGTGGGCCTCTGTTCCTTTCTCT 
LAMP1 3’UTR reverse: CGCTGTTTAAACAGCTGGTCCCGTGTACAATC 
IFN- 3’UTR forward: CGCTACTAGTGGTTGTCCTGCCTGCAATA 
IFN- 3’UTR reverse: CGCTGTTTAAACTTCCATTTGGGTACAGTCACAG 
Amplified 3’ UTRS were run in a 1.5% agarose gel and were excised and eluted using the 
innuPREP Gel Elution kit (Analytic Jena). pMIR-LAMP1-3’UTR (LAMP1-3’UTR) and 
pMIR-IFN--3’UTR (IFN- 3’UTR) were then generated by cloning the obtained PCR 
products into the Pme1 and Spe1 restriction sites of pMIR-RL plasmid using the T4 DNA 
ligase (Roche) (Figure 11). 
3’UTR sequences containing mutations in miR-27a and miR-24 binding sites for IFN- (IFN-
-mut UTR) and mutations in miR-23a binding sites for LAMP1 (LAMP1-mut UTR) 
(compare Figure 21) were chemically synthesized (Genewiz, Sigma Aldrich). These mutated 
3’ UTRs were then fused to the firefly luciferase gene in the pMIR-RL plasmid between the 
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Pme1 and Spe1 restriction sites to generate the pMIR-IFN--mut 3’UTR and pMIR-LAMP1-
mut 3’UTR constructs, respectively. 
 
 
 
 
Figure 11: pMIR RL, pMIR-LAMP1-3’UTR, pMIR-IFNG-3’UTR vector maps (created using Snapgene 
viewer). 
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4.15 Transfection of HEK293T cells and dual reporter gene assays 
1x10
4
 HEK293T cells/well were seeded in a 96 well flat bottom plate (TPP, Trasadingen, 
Switzerland) and adhered overnight. Transfection with pMIR-LAMP1-3’UTR, pMIR-IFN--
3’UTR , pMIR-LAMP1-mut 3’UTR, pMIR-IFN--mut 3’UTR or pMIR-RL either alone or in 
combination with miRNA mimics, miRNA antagomirs or control RNA (All Stars Negative 
Control siRNA from Qiagen) was performed, using the X-treme GENE siRNA Transfection 
Reagent (Roche Applied Science, Mannheim, Germany). Briefly, 100 µl of transfection 
complex were prepared with 1 µg of plasmid DNA and 200 nM miRNA mimics, antagomirs 
or control RNA and 30 µl were added per well. After the specified incubation time, 
supernatant was removed and the cells were lysed using 60 µl of Reporter Lysis Buffer 
(Promega). After one freeze-thaw cycle at -20°C, firefly and Renilla luciferase activities were 
measured using a non-commercial dual luciferase assay system (131).  
 
 
 
In short, 25 µl of cell lysate were transferred into each well of an opaque 96 well plate 
(Lumitrac 200, Greiner Bio-One, Frickenhausen, Germany) and luciferase activities were 
measured on an Orion Microplate Luminometer (Berthold Detection Systems, Pforzheim, 
Germany) using automated consecutive injection. Background values were obtained from 
untransfected cells. Relative light units (RLU), i.e. the ratio of background-subtracted firefly 
to Renilla luciferase signals were normalized to the reporter plasmid without 3´UTR (pMIR-
RL) or to the control RNA transfected group. 
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4.16 Degranulation assay 
In order to quantify degranulation, anti-CD107a/LAMP1-PE (clone: H4A3, BioLegend) or a 
PE-conjugated, isotype-matched control antibody (clone: MOPC21, BioLegend) was added 
directly to CD8
+
 T cells. After 1 h, 2 µM monensin (BioLegend) was added. 4 h later, the 
cells were washed and stained with anti-CD8 PE-Cy5 (clone: HIT8, BioLegend) and anti-
CD3 APC (BioLegend) antibodies and the expression of CD107a on CD8
+
 T cells was 
measured by flow cytometry.  
4.17 Quantification of proteins in cell lysate 
Total protein concentration in cell lysates used for immunoblotting was determined by 
Bradford assay. 50 µl of distilled water was loaded in every well of a 96-well plate, then 1 µl 
of protein lysate or Protein standard (HSA) was loaded in triplicate. For the standard row, 
protein concentrations of 1, 2, 4, 6, 8, 10 and 12 µg/ml were used. Thereafter, Rotiquant 
Bradford reagent was diluted by 1:3.75 with distilled water, and then 200 µl of this solution 
were added to each well. After 20 min at room temperature, total protein concentration was 
determined in an ELISA reader by measuring the absorbance at 595 nm. 
4.18 Immunoblot analysis  
Total LAMP1, DAP10 and phospho-SMAD-2/3 in cells were analyzed by immunoblot. In 
short, cells were collected by centrifugation, washed with PBS and lysed in protein lysis 
buffer containing 50 mM Tris-HCl (tris(hydroxymethyl)aminomethane-hydrochloric acid) pH 
8.0 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), 120 mM sodium chloride, 5 mM 
EDTA, 2 µg/ml Aprotinin, 10 µg/ml Leupeptin, 1 mM PMSF, 10 nM sodium fluoride (all 
purchased from Carl Roth, Karlsruhe, Germany), 0.5% Nonidet P-40 and 1 mM sodium 
orthovanadate (both from Applichem GmbH, Darmstadt, Germany). 10-20 µg proteins were 
separated on a 10% polyacrylamide (Carl Roth) gel under reducing conditions, transferred to 
a PVDF membrane (Carl Roth) which was blocked in PBS containing 5% skimmed milk 
powder and 0.05% Tween20 (both from Carl Roth) and incubated overnight at 4°C with 
either 0.5 µg/ml LAMP1 antibody (clone H4A3, BioLegend), 0.5 µg/ml DAP10/HCST (# 
AP16996PU-N, Acris Antibodies, Herford, Germany) or with, 1:1000 dilution of p-SMAD 
2/3 antibody (#8828- Cell Signaling). GAPDH (clone EPR1977Y, Epitomics, Burlingame 
CA.) or -actin (clone: 2F1-1, Biolegend) served as relevant loading controls.  Proteins were 
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visualized using horseradish peroxidase-coupled species specific secondary antibodies (anti-
mouse, anti-goat or anti-rabbit IgG secondary antibody from KPL, Wedel, Germany) and 
homemade enhanced chemiluminescence (ECL) solution. ECL solution was prepared by 
mixing 0.25 mg/ml Luminol (Carbosynth Ltd, Berkshire, UK) in 0.1 M Tris-HCL (pH 8.6) 
with 1.1 mg/ml para-hydroxycoumaric acid (Sigma-Aldrich) and 30% hydrogen peroxide 
(Carl Roth) at a 10:1:0.003 ratio.  
4.18.1 Buffers used for immunoblotting: 
Blocking Buffer: 5% skim milk powder in PBS-T. PBS-T: PBS + 0.05% Tween20. Protein 
loading buffer (5x): 100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% Bromophenol blue, 0% 
Glycerol, 10% β-Mercaptoethanol. Gel running buffer: 25 mM Tris. 193 mM Glycin, 0.5% 
SDS pH 8.8. Gel to PVDF transfer buffer: 25 mM Tris, 192 mM Glycin, 20% Methanol. 
4.19 Surface staining for NKG2D receptor expression 
Cells were harvested and washed once with PBS and again with FACS buffer (PBS+ 2% 
FBS). Unspecific antibody binding was blocked with 0.5% normal rabbit serum. PE 
conjugated Anti-human NKG2D antibody (mouse monoclonal; clone: BAT221; Miltenyi 
Biotec) or an isotype control was added and incubated for 30 min on ice. Cells were then 
washed twice with PBS and analyzed on a FACSCalibur™ (BD Biosciences).  
4.20 Intracellular staining for IFN-and CD107a/LAMP1 
Cells were treated with 2 µM monensin for 4 h. Afterwards, they were harvested by 
centrifugation and washed with ice cold PBS.  All downstream processes were performed on 
ice. Unspecific antibody binding was blocked with 0.5% normal rabbit serum for 15 mins. 
Cells were then stained with PE-Cy5-conjugated anti-CD8 (Biolegend) and APC-labeled anti-
CD3 (Biolegend) antibodies. They were fixed in 4% paraformaldehyde solution for 15 min 
and washed with PBA buffer (1% BSA in PBS). Cells were permeabilized by incubating them 
for 15 min in 0.5% Saponin (Carl Roth) (in PBA buffer). After one wash, intracellular 
stainings were performed with PE-labeled anti-IFN- (clone 4S.B3, Biolegend) in 
permeabilization buffer or with anti-CD107a/ LAMP1 antibodies and analyzed on a 
FACSCalibur™ (BD Biosciences). 
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4.21 ELISA  
To quantify secreted IFN-, cells were centrifuged at 300g for 10 minutes and the supernatant 
was transferred to a fresh 1.5 ml tube. This tube was centrifuged at 15,000 g for 10 minutes 
and the supernatant was collected and stored at 4°C until use. In order to quantify intracellular 
IFN-, cells were harvested by centrifugation at 300g for 10 minutes. Protease-free buffer was 
prepared by mixing 2 µg/ml aprotinin, 10 µg/ml leupeptin and 1 nM PMSF in PBS and the 
cells were lysed in this buffer by 4 freeze-thaw cycles at -20°C. Secreted and intracellular 
IFN- was quantified by ELISA. The antibodies (capture and detection) and IFN- standard 
were from the IFN- high sensitivity human ELISA set Immunotools, Friesoythe, Germany). 
Briefly, anti-human IFN-capture antibody  was diluted (1: 2000) in coating buffer (100 mM 
Na2CO3, pH 9.6) and was coupled to a Maxisorp™ 96 well plate (Nunc, Roskilde, Denmark). 
The plate was incubated at 4°C overnight and was washed 5 times with wash buffer (0.01% 
Tween 20 in PBS. Unspecific antibody binding was then blocked by incubating the plate in 
blocking buffer (1% BSA in PBS) for 1 h at room temperature followed by 5 washes with 
wash buffer. IFN- standard concentrations (ranging from 0.078 ng/ml up to 5 ng/ml) and a 
blank control were prepared in dilution buffer (1% BSA and 0.05% Tween 20 in PBS) and 
100 µl from each were pipetted in duplicates into the plate. 100 µl of cell supernatants were 
also added into separate wells in duplicates. The plate was then incubated for 1 h at room 
temperature and washed 5 times with wash buffer. Biotinylated anti-human IFN- detection 
antibody mixed (1: 2000) in dilution buffer was added for 1 h at room temperature and the 
plate was washed 5 times with wash buffer. The plate was further incubated for 30 min with 
Streptavidine-HRP (Immunotools) diluted (1:7500) in dilution buffer. After washing 5 times 
with wash buffer, substrate solution* was added for 20 minutes to enable color development. 
The reaction was stopped using 2N sulphuric acid. Absorbance was measured at 450 nm in a 
Sunrise microplate reader (Tecan, Crailsheim, Germany) and cytokine concentrations were 
determined based on the standard row using the Magellan analysis software (Tecan). 
* Substrate solution: 5 ml of 42 mM TMB (3,5,3’,5’-tetramethylbenzidine) solution in DMSO 
and 500 ml of 0.1 M sodium acetate solution were mixed. Into 10 ml of this solution, 2 µl 
hydrogen peroxide was added and used as substrate solution.  
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4.22 CD8+ T cell cytotoxicity assay 
10
4
 FM55 melanoma cells were seeded per well in a 96 well plate in complete RPMI 1640 
medium. On the next day, 10
4
 Melan-A-specific CD8
+
 T cells were added for 4h. Then, 
CellEvent
TM
 Caspase 3/7 Green detection reagent (Life technologies) was added to a final 
concentration of 4 µM and incubated for additional 30 minutes. The cells were then harvested 
using Accutase (Sigma Aldrich) and stained with anti-CD8-PE-Cy7 (Biolegend) to 
discriminate between CD8
+
 T cells and (Melan-A-expressing) tumor cell targets. From the 
latter subset, the percentage of cells showing caspase 3/7 activity was analyzed by flow 
cytometry (Attune
®
, Life technologies). To assess the effect of the miR-23a cluster on the 
cytotoxic activity of a CD8
+
 T cell clone, STEAP-specific T cells were nucleofected with 
miRNA mimics or control RNA and 10
4
 MCF-7 breast cancer cells were seeded 10
4
  in a 96 
well plate. On the following day, the tumor cells were loaded with the STEAP peptide (5 
µg/ml) in the presence of IFN-(10 ng/ml). 24 h later, 104 STEAP-specific CD8+ T cells were 
added and the cytotoxic activity was assessed as described above.  
4.23 Statistics 
P values for the microarrays were calculated with the miRXplorer software based on a 
comparison between the mean ratio of 4 replicates and the error of the respective mean ratio 
with the Gaussian error function. To calculate the cumulative effect of miRNA induction for 
miR-23a, -27a, and -24, the CT values obtained from qRT-PCR were transformed to z-scores 
before standard ANOVA was performed for the 4 respective groups. Unless mentioned 
otherwise, significance was determined by Student’s t test, and P < 0.05 was considered 
significant. 
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5 Results 
5.1 miR-23a cluster is induced by TGF- in CD8+ T cells 
5.1.1 miRNA microarrays 
We determined TGF- mediated regulation of the CD8+ T cell miRNome using an overlap 
approach employing miRNA microarrays and next generation sequencing. For this, we 
prepared 3 groups of cells. Cells were activated for 24 h using T cell activation beads 
(described above) and treated with either 5 ng/ml TGF-, 1 µM SD-208 or were left untreated 
(control group). SD-208, a TGF- receptor 1 kinase inhibitor, blocks TGF- signaling and 
was included in order to account for endogenous TGF- signaling. In order to exclude the 
interference of bovine TGF- in FBS, we cultured the cells in X-Vivo15 medium which is 
serum-free. We confirmed the induction of the TGF- signaling pathway upon TGF- 
treatment in these cells by analyzing SMAD 2/3 phosphorylation 15 minutes after treatment 
(Figure 12A) and the down regulation of NKG2D receptor 24 h after treatment (Figure 12B) 
(132). Data from representative donors is shown. 
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Figure 12. Validation of TGF- signaling. (A) CD8+ T cells were activated for 24 h using T cell activation 
beads and then treated with 5 ng/ml TGF- or 1 µM SD-208 for 15 minutes. In order to control the potency of 
SD-208, some cells from this donor were also pre-treated for 10 minutes with 1 µM SD-208 followed by the 
addition of 5 ng/ml TGF- for 15 minutes. Untreated cells served as control. Cells were lysed and 5 µg of total 
protein lysate was separated in a poly acrylamide gel under reducing conditions. The amount of phospho-SMAD 
2/3 was determined by immunoblotting. -actin was used as loading control.  (B) CD8+ T cells were activated 
for 24 h and treated with either 5 ng/ml TGF-, 1 µM SD-208 or were left untreated (control group) for 24 h. 
NKG2D expression on the cell surface was quantified by flow cytometry. Specific fluorescence indices (SFI) 
were calculated by taking the ratio between the median fluorescent signal obtained with the specific antibody 
staining to that obtained with the isotype antibody. 
 
After confirming that TGF- signaling had occurred, cells from 5 donors per treatment group 
were individually snap-frozen in liquid nitrogen and shipped to Miltenyi Biotec on dry ice. 
Cells belonging to the same treatment group were pooled across the different donors and total 
RNA was isolated. Cells were pooled in order to even out donor dependent variations as well 
as to obtain a sufficient quantity of RNA for hybridization.  Quality of RNA was checked on 
the Agilent 2100 Bioanalyzer platform (Agilent Technologies). The results of the Bioanalyzer 
run were visualized in a gel (Figure 13A) and an electropherogram (Figure 13B). The 2 
prominent peaks in the electropherogram indicate 28S and 18S ribosomal RNA. Peaks 
between 25 and 200 nucleotides confirmed the presence of 5S ribosomal RNA, transfer RNAs 
and miRNAs. 
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Figure 13. Visualization of total RNA. (A) Gel image where the first lane shows an RNA molecular weight 
ladder (in nucleotides, nts).  The lowest migrating green band is an internal standard. (B) Electropherogram after 
RNA isolation. 
 
Fluorescence signals from the microarrays were detected using a laser scanner (Agilent) and 
the false-color images are shown (Figure 14). A red spot indicates that the Hy5 signal was 
higher than the Hy3 signal, a green spot indicates the opposite and a yellow spot indicates 
similar Hy5 and Hy3 signal intensities. 
 
Figure 14. Hy5/Hy3 false-color image after scanning of the microarrays. Using the PIQORTM 
Analyzer, mean Hy5/Hy3 ratios for all miRNAs were calculated to obtain the miRNA variations in the TGF- 
group relative to both the control and SD-208 treated group. 
 
5.1.2 Next generation sequencing (deep sequencing or libraries) 
CD8
+
 T cells from 5 donors were prepared and treated exactly as done for the microarrays. As 
described in the methods section, from the annotated reads the normalized read numbers for 
each miRNA were derived and the fold changes of the miRNAs in the TGF- group relative 
to the control and the SD-208 group were determined. These changes differed from the ratios 
obtained from the microarrays. We believe that these variations are due to the inherent 
differences between the 2 techniques. Such discordances and their reasons have been reported 
previously (133, 134). Reads that were still not annotated as a known miRNA could have 
been fragments of longer RNAs, sequencing errors or more interestingly, previously 
unidentified miRNAs. 
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5.1.3 Identification of new miRNAs 
15-25 base long RNA reads showing no less than 50 reads per sequence were aligned against 
the human genome (both + and -). Sequences that showed 100% homology were chosen as 
primary candidates for new miRNAs. Some of the sequences aligned to multiple 
chromosomes, which was not surprising considering the short size of miRNAs and the fact 
that similar sequence miRNAs occur throughout the genome. Then, 50-100 bases either 
upstream or downstream of the sequences were retrieved and the secondary structures were 
analyzed for their characteristic stem loop formation shown by miRNA precursors. Since pri-
miRNAs and polycistronic miRNA transcripts can have multiple stem loops and since their 
fragments could also be within the sequences reads, we included such secondary structures 
also among the potential candidates. To this end, sequences were folded in silico using the 
RNAfold WebServer. Options to obtain minimum free energy (MFE) of folding and 
secondary structure of folding were included in the query along with the sequence. Some of 
the secondary structures that looked similar to miRNA precursors with sufficiently favorable 
MFE are shown below. 
 
Sequence A: TCCCACCGCTGCCACC 
a. Location: Chromosome 14 (Start = 56043519 Stop = 56045534) 
Folding region: 
AAGGCCCGCAGCAGCACACAGAAGCCCAGAGGGGAGGGTGGCAGCGGTGGGAG 
 MFE: -22.29 kcal/mol 
 
b. Location: Chromosome 3 (Start = 34575158 Stop = 34577173) 
Folding region: 
GTCCCACCGCTGCCACCCTCCCCTCTGCCTCAGTGTGCCAGGCATCAGCACTCACTCACAGAGGCA
GGCTGGATGGCGGGTGGGAC 
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 MFE: -45.08 kcal/mol 
c. Location: Chromosome 7 (Start = 6148710 Stop = 6150725)  
Folding region: 
TTCTCTCTTGGCTTCCTGCCATTTCTTCCACAGGTGGCAGCGGTGGGAGCGA 
MFE: -18.59 kcal/mol 
 
This sequence had been annotated as miR-1280 after we had sequenced the libraries. 
However, its miR status was later withdrawn citing the probability that it could be a t-RNA 
fragment. 
 
Sequence B:  CTCCCACTGCTTCAACT 
a. Location: Chromosome X (Start = 835965 Stop = 837981) 
Folding region: 
ATATATATATACATATATATACAGTATATCAGTATATATACGTGTGTGTGTATATATATATATATAT
GTAATAAGCATCCAAGAAAAACAGAGCTGCTTCAGTTGAAGCAGTGGGAGGCT 
(Region ahead of the miRNA sequence shows this folding. Folded Region shown in Green) 
MFE: -24.86 kcal/mol 
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b. Location: Chromosome 9 (Start= 10820180 Stop= 10820196) 
Folding region: 
CAGAATGGGTCACGCTCAGGCAGGTCTTACAGGCATGCCATGCTCTCTTACACACGGTATGGCTCA
GCTGATTGTAGCACCTGTTGTCCTCCCACTGCTTCAACT 
MFE: -34.29 kcal/mol 
 
c. Location: Chromosome 5 (Start= 12327573 Stop= 12327557) 
Folding region: 
CCAGCTGAGGAGCAGTTGAAGCAGTGGGAGACACAGCCAGGTTTCTATTCAGTGTTGCTGG 
MFE:  -16.94 kcal/mol. 
 
Sequence C: TTCTCACTACTGCACTTGAA 
Location: Chromosome 2 (Start = 34096014 Stop = 34098032) 
Folding region: 
CTTCAATGAACATACATGATTTGAGAAAACAAAAAGGTGACAATGTATCTTTTTATTTTTAAACCA
GTCAAGTGCAGTAGTGAGAAG 
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MFE: -15.46 kcal/mol. 
This sequence showed 80% homology to the stem loop of cer-miR-248. 
Sequence D : GAAGCGGGTGCTCTTATTTT 
Location: Chromosome 10 (Start = 18075498 Stop = 18075517) 
Folding region: GGAAGCGGGTGCTCTTATTTTTTCTATTTTTTTAAATAAACACCTTC 
 MFE: -5.9 kcal/mol 
This sequence was previously investigated by our collaborators. It was mapped downstream of a tRNA 
sequence. No activity was detected in reporter gene assays as well as no binding to Ago proteins was observed. 
Hence it is unlikely to be a functional miRNA. 
5.2  Comparison of miRNA arrays and deep sequencing 
Significantly (p< 0.05) regulated miRNAs from the arrays were compared to their regulation 
in the libraries and are listed in Table 3. 
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miRNA 
Array Library 
TGF-/ control TGF- / SD208 TGF- / control TGF- / SD208 
hsa-let-7b 1.306 1.936 0.330 0.368 
hsa-miR-101 1.345 4.054 0.776 0.748 
hsa-miR-140-5p 1.362 2.896 1.854 1.023 
hsa-miR-146a 2.278 2.064 0.734 1.039 
hsa-miR-150 0.749 0.373 0.670 0.620 
hsa-miR-15a 1.458 4.557 0.806 0.948 
hsa-miR-16 1.011 0.859 0.872 0.796 
hsa-miR-17 1.457 0.879 0.996 0.781 
hsa-miR-181a 1.649 1.558 0.831 0.682 
hsa-miR-21 1.301 3.563 1.057 1.358 
hsa-miR-22 1.660 1.881 0.834 1.047 
hsa-miR-23a 1.502 1.184 1.150 1.707 
hsa-miR-23b 1.953 1.314 1.071 1.008 
hsa-miR-24 1.043 1.226 1.400 1.254 
hsa-miR-25 3.092 1.779 1.085 0.906 
hsa-miR-26b 4.418 2.220 0.990 1.051 
hsa-miR-27a 1.878 2.484 1.134 1.636 
hsa-miR-27b 2.251 4.355 0.777 0.793 
hsa-miR-30b 1.467 1.138 0.660 1.254 
hsa-miR-30c 1.860 1.752 0.821 1.243 
hsa-miR-30d 1.223 1.183 1.104 0.842 
hsa-miR-361-5p 2.421 3.392 1.300 1.249 
hsa-miR-93 2.330 7.078 1.448 0.942 
hsa-let-7a 0.981 0.765 1.545 0.813 
hsa-let-7f 1.360 1.165 1.247 0.896 
hsa-miR-103 0.798 0.858 1.185 1.019 
hsa-miR-107 0.793 0.846 1.351 1.295 
hsa-miR-142-3p 1.161 2.859 0.921 0.996 
hsa-miR-19a 1.209 1.891 2.142 14.369 
hsa-miR-20a 1.138 1.282 0.944 0.819 
hsa-miR-20b 1.014 1.418 0.461 0.334 
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hsa-miR-106b 0.885 1.247 1.221 1.570 
hsa-miR-335 0.790 1.517 0.212 1.105 
hsa-miR-29b 1.319 2.545 0.801 0.891 
hsa-miR-92a 1.604 1.608 0.881 0.854 
hsa-miR-342-3p 0.730 0.455 1.155 0.777 
hsa-let-7i 1.249 1.512 1.812 1.351 
hsa-miR-142-5p 1.133 1.871 0.422 0.609 
hsa-miR-191 0.772 0.645 1.050 0.966 
hsa-miR-212 1.055 2.137 0.456 0.884 
hsa-miR-26a 0.733 0.595 0.911 0.892 
hsa-miR-29c 1.571 1.992 0.821 1.144 
hsa-miR-30e 1.269 2.257 1.005 1.263 
hsa-miR-30e* 1.111 1.490 1.327 1.253 
hsa-miR-769-5p 1.000 3.376 0.741 0.276 
hsa-miR-320b 1.568 2.274 2.307 1.934 
 
Table 3. miRNA fold changes in the libraries and arrays. We selected miRNAs that showed statistically 
significant (p< 0.05) regulations and were at least 20% up or down regulated in the TGF- group relative to the 
SD-208 treated group in the arrays and compared the fold changes of these miRNAs in the libraries.  
 
To visualize the overlap between the arrays and libraries, we generated a Venn diagram from 
the miRNAs in table 1 (Figure 15). 
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Figure 15. Library vs array.  The Venn diagram shows the overlap of regulations between the TGF- treated 
group and the SD-208 treated group in the libraries and arrays. miRNAs which were at least 20% up or down 
regulated were included in the comparison. The Venn diagram was generated using the freely available online 
tool Venny (135). 
 
As one can observe, several miRNAs showed discordant regulations in the arrays and 
libraries. A comparison between the 2 platforms is, however, not the major focus of this 
study, so we searched for the overlap between the two techniques in order to obtain reliable 
candidates for further validation. Hence, 13 miRNAs which were significantly regulated in 
the arrays (p<0.05 for TGF- vs. SD-208 treated groups) and which also showed somewhat 
similarly directed (up or down) regulations in the miRNA libraries are shown in (Table 4) and 
were selected for further validation by qRT-PCR. 
Table 4. 
miRNA 
Array Library 
TGF-/ control TGF-/ SD208 TGF-/ control TGF-/ SD208 
1 hsa-miR-21 1.30 3.56 1.06 1.36 
2 hsa-miR-361-5p 2.42 3.39 1.30 1.25 
3 hsa-miR-140-5p 1.36 2.90 1.85 1.02 
4 hsa-miR-27a 1.88 2.48 1.13 1.64 
5 hsa-miR-320b 1.57 2.27 2.31 1.93 
6 hsa-miR-30e 1.27 2.26 1.01 1.26 
7 hsa-miR-19a 1.21 1.89 2.14 14.37 
8 hsa-let-7i 1.25 1.51 1.81 1.35 
9 hsa-miR-30e* 1.11 1.49 1.33 1.25 
10 hsa-miR-24 1.04 1.23 1.40 1.25 
11 hsa-miR-23a 1.50 1.18 1.15 1.71 
12 hsa-miR-26a 0.73 0.59 0.91 0.89 
13 hsa-miR-150 0.75 0.37 0.67 0.62 
 
5.3 qRT-PCR validation of miRNA regulations 
CD8
+
 T cells from 3 different donors were isolated and activated for 24 h. The cells were then 
treated with either 5 ng/ml TGF-, 1 µM SD-208 or were left untreated for 24 h. We did not 
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pool the individual groups from various donors. miRNA cDNA was prepared using a 
universal reverse primer as described in the methods section.  
The efficiency of our technique to robustly amplify mature miRNAs was tested. Sybr green 
based quantification enabled validation of end product purity through the dissociation curve. 
A single curve indicated one specific product (Figure 16A). In order to confirm that we were 
indeed amplifying the mature miRNA and not the stem loop precursor, we amplified miRNAs 
arising from the 5’ end and 3’ end of the stem loop precursor and analyzed the products on a 
gel. If the templates were the stem loop precursors, then the amplicons from miRNAs in the 
5’ end should be longer than the ones from the 3’ end and this was not the case (Figure 16B). 
Each miRNA amplicon was nearly 50 bases long because of the addition of the poly-A tail 
and subsequent binding of the URT primer. 
 
Figure 16. Substantiation of miRNA amplicons. (A) Dissociation (melting) curve of miR-27a generated by the 
ABI7500 fast software (Applied Biosystems) after amplification of the miRNA. (B) qRT-PCR products were run 
on a 3% agarose gel and visualized under UV-light.  
Only the 3 members of the miR-23a cluster namely miR-23a, miR-27a and miR-24 were 
consistently upregulated by TGF-. This upregulation was further upheld when tested in 2 
more donors (totally n=5) (Figure 17). Conversely, inhibition of TGF- signaling by SD-208 
reduced their expression of the miR-23a cluster. Although there were slight regulations for the 
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other miRNAs, donor variability was pronounced and thus they were not considered for 
functional validations. 
 
Figure 17. Regulation of miR-23a cluster in CD8
+
 T cells after treatment with TGF-CD8+ T cells were 
isolated, activated and either left untreated (control) or treated with TGF- (5 ng/ml) or SD-208 (1 µM) for 24 
or, respectively, 72 hours. miRNA expression was quantified by qRT-PCR using U6 snRNA as internal 
reference. Relative expression was normalized to control. Average levels of induction (± SD) from different 
donors are shown (n=5 for 24 h, n=3 for 72 h time-point). p-values were determined using unpaired Student’s t-
test (* p<0.05, ** p<0.01, *** p<0.001). 
 
miR-23a, miR-27a and miR-24 were upregulated by TGF- in murine CD8+ T cells. 
TGF- signaling involving SMADs is highly conserved in metazoans (136). The similarities 
in molecular targets (including those involved with immune responses) of TGF- signaling 
have been extensively compared in mouse and human systems. To confirm the link between 
TGF- signaling and induction of the miR-23a cluster, we further used CD8+ T cells obtained 
from the spleen of either wild-type Balb/cJ mice or from mice overexpressing a dominant 
negative TGF- type II receptor under control of the human CD2 promoter (hCD2-∆kTRII) 
(123). This presented us a system with genetically impaired TGF- signaling.  Similar to 
human cells, also CD8
+
 T cells from wild type mice showed an induction of miR-23a, miR-
27a and miR-24 upon TGF- treatment. However, cells from hCD2-∆kTRII mice (which 
lack the intracellular kinase domain) did not show an induction of these miRNAs (Figure 18). 
Due to the low number of animals available for this experiment (4 wild-type and 3 transgenic 
mice), this induction did not reach statistical significance for individual miRNAs (p>0.05). 
Nevertheless, when z-scores of respective CT values of the miRNAs from the qRT-PCR were 
taken, ANOVA analysis showed that the miR-23a cluster as a whole was significantly 
(p<0.05) upregulated in CD8
+
 T cells from wild type mice, but not in cells from hCD2-
∆kTRII mice. Thus, the TGF- dependent induction of the miRNA-23a cluster which had 
been found in activated and resting human CD8
+
 T cells could also be confirmed ex vivo in 
transgenic mice expressing a dominant-negative receptor for TGF-. As basal levels of the 
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miR-23a cluster members were not reduced in hCD2-∆kTRII mice, TGF- might act as an 
inducer of these miRNAs without being required for baseline expression. Alternatively, 
compensatory mechanisms could be operational in mice expressing the dominant-negative 
TGF- receptor. 
 
 
Figure 18. Induction of mouse miR-23a cluster by TGF-. CD8+ T cells were purified from the spleen of 
hCD2-∆kTRII mice overexpressing a dominant negative form of the TGF- type 2 receptor (DN-Tg) (n=3) and 
from wild-type mice (WT) (n=4). These cells were activated for 24 h using anti-CD3 and anti-CD28 antibodies 
in the presence or absence of 30 ng/ml TGF-1. Cells were lysed and total RNA was isolated, poly-adenylated 
and cDNA was prepared. qRT-PCR was performed to quantify miRNA expression using SNORD70 RNA as an 
internal reference. Relative expression was averaged within the WT or DN-Tg groups and is shown. To analyze 
the regulation of the miR-23a cluster, z-scores of mean CT values were taken and analyzed by ANOVA 
(p<0.05). 
 
5.4 The 3’UTRs of LAMP1 and IFN- contain binding sites for members 
of the miR-23a cluster  
To search for putative targets of the miR-23a cluster, online miRNA target prediction tools, 
namely Targetscan (www.targetscan.org), miRanda (www.mirna.org) and DIANA-microT-
CDS (diana.cslab.ece.ntua.gr/micro-CDS/?r=search) were employed. Among the predicted 
target mRNAs CD107a/LAMP1 and IFN- stood out as they are both involved in TGF- 
sensitive immunological pathways (73, 137), and may hence be of particular relevance for 
miRNA-mediated, TGF- dependent immunomodulation. CD107a/LAMP1 has two putative 
binding sites for miR-23a in its 3’UTR and the 3’UTR of IFN- contains complementary 
regions for both miR-27a and miR-24 (Figure 19). 
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Figure 19. Predicted binding sites of the miR-23a cluster on IFN- and LAMP1 3’ UTRs. Shown are the 
alignments of miR-23a, miR-27a and miR-24 on the respective mRNA 3’UTRs (Figure source: miRanda 
(microRNA.org)). 
 
5.4.1 Cloning reporter gene constructs 
The respective 3’UTRs of IFN- and LAMP1 were amplified from CD8+ T cell cDNA using 
primers with Pme1 or Spe 1 restriction sites (Figure 20). The amplified 3’UTRs were then 
fused to the firefly luciferase gene in the modified pMIR-RL plasmid to generate pMIR-
LAMP1-3’UTR and pMIR-IFN--3’UTR.  
 
Figure 20. 3’ UTR of IFN- and LAMP1. RNA from CD8+ T cells was isolated using Tri Reagent (Sigma-
Aldrich) following the manufacturer’s instructions. 0.5 µg of total RNA was reverse transcribed using iScript 
Reverse Transcription kit (Biorad). Using 25 ng of cDNA as template, the 3’UTRs of IFN- and LAMP1 mRNA 
were amplified with the respective primers using the Crimson LongAmp polymerase (NEB). The figure shows 
the 3’ UTRs after resolving them on a 1.5% agarose gel. 
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In order to further confirm the specificity of the miRNA binding to the respective 3’ UTRs, 
we mutated nucleotides within the miRNA binding site to eliminate complementarity (Figure 
21). Such mutated 3’UTRs were chemically synthesized and fused to the firefly luciferase 
gene to generate pMIR-LAMP1-mut 3’UTR and pMIR-IFN--mut 3’UTR constructs. This 
was achieved by introducing 3 to 6 point mutations into each binding site. To maximize 
repulsion between the miRNA and the 3’UTR at these mutated sites, purines were replaced by 
pyrimidines and vice versa. 
 
Figure 21. Mutated seed sequences. The illustration shows an alignment of the miRNA binding regions of wild 
type URT with the mutated 3’UTR. ‘*’ sign indicates a mutation at that point. 
 
5.4.2 miRNA-23a targets the 3’UTR of LAMP1 
We performed reporter gene assays using modified pMIR-RL constructs containing the 3’ 
UTR of the putative target mRNA fused to the coding sequence of firefly luciferase which is 
expressed under a herpes simplex virus thymidine kinase (HSV-TK) promoter. As a robust 
transfection system, we used HEK293T cells. HEK293T cells were transfected with a 
luminescent miRNA reporter construct containing the 3’UTR of LAMP1 (pMIR-LAMP1-
3’UTR). Increased firefly luciferase activity was observed when endogenous miR-23a was 
blocked by the respective antagomir whereas blockade of miR-27a or miR-24 or addition of 
an antagomir against the non-expressed (brain-specific) miR-9 (138) showed no significant 
effect (Figure 22A, left). Conversely, overexpression of miR-23a reduced the luciferase 
signal while miR-27a and miR-24 or addition of control RNA did not affect luminescence 
(Figure 22A, right). These data support the in silico prediction that miR-23a binds to the 
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3’UTR of LAMP1 and thereby leads to inhibition of protein synthesis. Moreover, miR-23a 
overexpression failed to silence firefly luciferase expression from the pMIR-LAMP1-mut 
3’UTR construct. This assay confirmed the specificity of the predicted miRNA binding 
(Figure 22 B).   
 
     
Figure 22. miR-23a can target LAMP1-3’UTR. Reporter gene assays were performed using unmodified or 
mutated 3´UTRs of LAMP1. HEK293T cells were thus transfected with either pMIR-RL, pMIR-LAMP1-3’UTR 
or pMIR-LAMP1-mut 3’UTR alone (-) or in combination with antagomirs against miR-9 (ant-9) as control, 
miR-23a (ant-23a), miR-27a (ant-27a), miR-24 (ant-24) or all 3 together (ant-23a, 27a, 24) respectively. 
Likewise, mimics for miR-23a (mimic-23a), miR-27a (mimic-27a), miR-24 (mimic-24), all 3 together (mimic-
23a, 27a, 24) or negative control RNA (control RNA) were co-transfected with the reporter plasmids as 
indicated. 24 hours after transfection, the cells were lysed in Reporter Lysis Buffer (Promega) and a dual 
luciferase assay was performed. Relative light units (RLU) were calculated by taking the ratio of background-
subtracted firefly to renilla luciferase light units. The RLUs from the various constructs were then normalized to 
those obtained with pMIR-RL (in A) or to the group co-transfected with the respective construct and the 
irrelevant control RNA (in B). Transfections were performed in triplicates and a representative out of 3 
independent experiments is shown (± SD). p-values were determined using Student’s t-test (* p<0.05, ** p<0.01, 
*** p<0.001).  
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5.4.3 miR-24 and miR-27a target the 3’UTR of IFN- 
When HEK293T cells were transfected with a luminescent miRNA reporter construct 
containing the 3’UTR of IFN- (pMIR-IFN--3’UTR), increased firefly luciferase activity 
was observed upon suppression of endogenous miR-27a and miR-24. Inhibition of miR-23a 
or control transfection with an antagomir against miRNA-9 had no such effect (Figure 23 A 
left). On the other hand, over-expression of miR-27a and miR-24 significantly lowered firefly 
luciferase activity whereas the over-expression of miR-23a or transfection with control RNA 
did not affect luciferase activity (Figure 23A, right). The apparent lack of synergy between 
miR-27a and miR-24 which both bind to the same 3´-UTR may be explained by the total 
amount of mimics or antagomirs which was always kept constant. In addition, it is not clear 
whether independent binding of two different miRNAs can further enhance the transcriptional 
blockade achieved by binding of a single miRNA or whether limited availability of accessory 
proteins may restrict the total effect of miRNAs. Still, the reporter assay data clearly show 
that miR-27a and miR-24 both bind to the 3´UTR of IFN- and block protein synthesis. 
Again, mutation of the predicted binding sites on the IFN- 3’ UTR prevented the silencing of 
firefly luciferase gene upon overexpression of miR-27a and miR-24 (Figure 23B) confirming 
the specificity of miRNA binding to the proposed sites on the respective 3’UTRs which will 
then inhibit protein synthesis.  
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Figure 23. miR-27a and miR-24 can target IFN--3’UTR. HEK293T cells were transfected with either pMIR-
RL, pMIR-IFN--3’UTR or pMIR-IFN--mut 3’UTR alone (-) or in combination with antagomirs against miR-9 
(ant-9) as control, miR-23a (ant-23a), miR-27a (ant-27a), miR-24 (ant-24) or all 3 together (ant-23a, 27a, 24) 
respectively. Likewise, mimics for miR-23a (mimic-23a), miR-27a (mimic-27a), miR-24 (mimic-24), all 3 
together (mimic-23a, 27a, 24) or negative control RNA (control RNA) were co-transfected with the reporter 
plasmids as indicated. 24 hours after transfection, the cells were lysed in Reporter Lysis Buffer (Promega) and a 
dual luciferase assay was performed. Relative light units (RLU) were calculated by taking the ratio of 
background-subtracted firefly to renilla luciferase light units. The RLUs from the various constructs were then 
normalized to those obtained with pMIR-RL (in A) or to the group co-transfected with the respective construct 
and the irrelevant control RNA (in B). Transfections were performed in triplicates and a representative out of 3 
independent experiments is shown (± SD). p-values were determined using Student’s t-test (* p<0.05, ** p<0.01, 
*** p<0.001). 
 
5.5 The miR-23a cluster inhibits LAMP1 surface expression on activated 
CD8
+
 T cells  
TGF- mediated inhibition of activation and degranulation of cytotoxic CD8+ T cells has been 
described earlier (137). Since degranulation causes transient integration of CD107a/LAMP1 
into the outer cell membrane, lytic activity can be quantified via surface staining for LAMP1. 
However, the mechanism by which TGF- inhibits degranulation has not been described yet. 
As for potential direct miRNA-mediated effects on LAMP1, miRNAs can only inhibit 
synthesis of new LAMP1 protein through the 3’UTR. Hence, miRNAs are unlikely to be 
involved in rapid regulations which occur mainly by translocation. Therefore we first 
investigated the dynamics of LAMP1 expression during activation of CD8
+
 T cells. To this 
aim, we added the translation inhibitor cycloheximide (CHX) to a stimulation experiment. 
Immunoblotting revealed that CHX prevents the activation-dependent increase in total 
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LAMP1 expression. Basal LAMP1 levels, however, were hardly affected (Figure 24) 
indicating a very low turnover of LAMP1 protein (139, 140). (Immunoblot-based 
quantification is affected by the effect of CHX on the loading control (GAPDH) and thus 
mainly qualitative). 
 
Figure 24. Total LAMP1 levels after activation. In order to quantify total LAMP1, untouched CD8
+
 T cells 
were isolated and either rested or activated with anti-CD2, anti-CD3 and anti-CD28 coated beads, in the absence 
or presence of cycloheximide (CHX). After 48 h, cells were lysed and the protein was quantified using 
immunoblotting as described. 
 
We then attempted to study the kinetics of LAMP1 surface expression on CD8
+
 T cells after 
activation in the presence of CHX. As expected, non-activated CD8
+
 T cells express very 
little LAMP1 on the cell surface while activated cells showed a progressive increase of 
surface LAMP1 expression with time. However, when we stimulated cells in the presence of 
CHX, it showed little effect on surface LAMP1 at 6 h, but prevented the activation-induced 
display of LAMP1 at later time points (Figure 25).  
 
Figure 25. Effect of CHX on LAMP1 surface expression. CD8
+
 T cells were isolated and treated as in (Figure 
24). After 2 h, 20 h and 44 h, respectively, PE-conjugated anti-LAMP1 antibody or an isotype control antibody 
was added to the cells followed by monensin. 4 hours later, surface expression of LAMP1 was determined by 
flow cytometry. To obtain specific fluorescence intensity (SFI) values, the median fluorescence values obtained 
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with PE-conjugated anti-CD107a were divided by the median fluorescence values obtained with a PE-labeled 
isotype control antibody. 
 
While this effect of CHX could imply that surface LAMP1 expression is contributed by 
freshly translated LAMP1 (which would be sensitive to both miR-23a and CHX), it could also 
imply an effect of CHX on the myriad of proteins that are required for degranulation and/or 
vesicular transport. As LAMP1 is a highly abundant glycosylated protein with a rather long 
half life (nearly 2 days), Even the complete blockade of protein synthesis by cycloheximide 
affected its expression levels in activated T cells only slightly. Therefore, it was unlikely that 
the miRNAs could affect total LAMP1 pools in the cell in such a short period (139, 140). We 
put our hypothesis to the test by quantifying the effect of the miR-23a cluster on the 
activation-induced surface expression of LAMP1. Having found that the percentage of bead-
activated CD8
+
 T cells expressing CD107a/LAMP1 on the surface increased from about 20% 
at 6 h after stimulation to almost 70% after 48 h, we chose this later time point as a potential 
read-out for miRNA regulation. While this may appear rather late for the measurement of 
CD107a/LAMP1, any inhibition of translation (whether by CHX or by miRNAs) can only 
become relevant with time. As implied by the reporter gene assays, LAMP1 surface 
expression on T cells decreased when the miR-23a cluster was over-expressed, whereas 
higher LAMP1 surface expression was observed when the cells were nucleofected with 
antagomirs against the miR-23a cluster (Figure 26A).  
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Figure 26. Effect of miR-23a cluster on surface LAMP1 expression. CD8
+
 T cells were isolated and split up 
into 4 groups. Each group was nucleofected with either a cocktail of mimics for miR-23a, miR-27a and miR-24 
(mimic-23a, 27a, 24) or negative control RNA (control RNA) or a cocktail of antagomirs against miR-23a, miR-
27a and miR-24 (ant-23a,27a,24) or antagomirs against miR-9 (ant-9). The total concentration of nucleotides 
was kept constant at 300 nM. 12 h after nucleofection, the cells were activated with beads as in (Figure 12). 
After 48 hours, anti-LAMP1 PE antibody or an isotype control antibody was added to the cells followed by 
monensin. 4 hours later, the cells were analyzed for LAMP1 expression by flow cytometry. (A) A histogram 
from a representative experiment (n=3) is shown. In (B), fluorescence values from 3 independent experiments 
were plotted (± SD). p-values were determined using Student’s t-test. (p>0.05, * p<0.05, ** p<0.01, *** 
p<0.001) 
 
While this suggests that granule exocytosis by activated T cells requires additional production 
of LAMP1 which could be affected by miR-23a, we did not see any significant effect of the 
miRNAs on total LAMP1 in the cells. Alternatively, the probability of a yet unidentified 
protein (involved in granule trafficking or plasma membrane fusion) being additionally 
targeted by miR-23a would also lead to decreased LAMP1 cell surface expression. In both 
cases, induction of miR-23a will impair CD8
+
 T cell degranulation and thus contribute to the 
known effects of TGF-β. However, considering that the effect was only moderate, we did not 
investigate the multitude of transport proteins which could additionally be targeted by miR-
23a. 
5.6 miR-23a cluster inhibits IFN- expression in activated CD8+ T cells 
While TGF- is already known to control IFN- on transcriptional level (73), post 
transcriptional regulations are poorly understood. Our results from reporter gene assays (see 
Figure 23A and 23B) suggest that the miR-23a cluster (which can be induced by TGF-) 
could potentially modulate IFN- translation. Activation of CD8+ T cells with bead-bound 
agonistic antibodies against CD2, CD3 and CD28 led to IFN- secretion which could be 
detected after 6 h, reaching a maximum between 24 and 48 h (Figure 27). 
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Figure 27. Kinetics of IFN- secretion in activated CD8+ T cells. CD8+ T cells isolated from a healthy human 
donor were stimulated anti-CD2, anti-CD3 and anti-CD28 coated beads. Supernatant from these cells were 
collected after 6 h, 24 h, 48 h, 72 h, 5 days and 7 days. Concentration of IFN- in technical duplicates was 
quantified in these supernatants by sandwich ELISA as described in the Methods section. Experiment was 
performed twice using different donors and a representative experiment is shown. 
 
Nucleofection negatively affected the ability of cells to produce IFN-. We observed that 
nucleofected cells produced about 
1
/2 to 
1
/3 of that was produced by non-nucleofected cells. In 
order to allow sufficient time for the antagomirs to silence the respective miRNAs and the 
mimics to inhibit newly synthesized IFN-, we assessed effects of miRNAs on IFN- 
expression after 48 h of activation. ELISA measurements revealed significantly less IFN- in 
supernatants from CD8
+
 T cells in which the miR-23a cluster had been overexpressed 
compared to cells transfected with control RNA (Figure 28A). A shift in IFN-–FITC 
fluorescence further showed that overexpression of the miR-23a cluster reduces the average 
amount of IFN- per cell (Figure 28B) without necessarily lowering the percentage of IFN-+ 
cells – which would be compatible with a miRNA–mediated effect that may attenuate rather 
than abrogate protein production. 
 
 
Figure 28. miR-23a cluster overexpression inhibits IFN- production. To analyze the effects of miR-23a 
cluster overexpression, CD8
+
 T cells were isolated and nucleofected either with control RNA or a combination 
of mimics for miR-23a, miR-27a and miR-24, always keeping the RNA concentration constant at 300 nM. 12 h 
after nucleofection, the CD8
+
 T cells were activated using anti-CD2, anti-CD3 and anti-CD28 coated beads. p-
values were determined using Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001) from triplicate wells. (A) 
Following 48 h of activation, supernatants were collected and IFN- levels were quantified by ELISA as 
described in the Methods section. The nucleofected and stimulated cells were incubated with monensin for an 
additional 4 h before IFN- expression was determined by intracellular flow cytometry.  A histogram overlay of 
the intracellular IFN- staining in the cells is shown in (B). 
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In line with the pMIR reporter gene assays which had shown that miR-27a and miR-24, but 
not miR-23a, can target IFN- via its 3’UTR, intracellular cytokine staining indicated 
significantly lower IFN- levels in cells when either miR-27a or miR-24 was overexpressed 
whereas no change was observed upon overexpression of miR-23a (Figure 29).  
 
Figure 29. IFN- expression is specifically inhibited by miR-27a and miR-24 but not by miR-23a. To 
analyze the effects of overexpression of individual members of the miR-23a cluster, CD8
+
 T cells were isolated 
and nucleofected either with control RNA or with mimics for individual miR-23a cluster members or with their 
combination, always keeping the RNA concentration constant at 300 nM. 12 h after nucleofection, the CD8
+
 T 
cells were activated using anti-CD2, anti-CD3 and anti-CD28 coated beads. Following 48 h of activation, cells 
were incubated with monensin for an additional 4 h before IFN- expression was determined by intracellular 
flow cytometry. Specific fluorescence intensities from 3 independent experiments were determined by 
normalizing the median fluorescence of the IFN- antibody staining to that of an isotype control antibody and are 
plotted (±SD). p-values were determined using Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001). 
 
Surprisingly, we did not see any difference in secreted IFN- when the miR-23a cluster was 
silenced (Figure 30 A) using antagomirs against the cluster. However, when we analyzed the 
fairly small amount of residual IFN- protein in cell lysates, levels were significantly elevated 
after silencing of the miR-23a cluster. Again, cells transfected with the antagomir against the 
non-expressed miR-9 served as control (Figure 30 B). 
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Figure 30. Inhibition of the miR-23a cluster affects residual IFN- within the CD8+ T cells. To analyze the 
effect of silencing the miR-23a cluster on IFN- expression, CD8+ T cells were isolated and nucleofected with 
either 300 nM of combined antagomirs against miR-23a cluster members (ant-23a,27a,24) or with 300 nM of an 
irrelevant control antagomir against miR-9. 12 h after nucleofection, the cells were activated with anti-CD2, anti-
CD3 and anti-CD28 coated beads. Following 48 h of activation, supernatants were collected and secreted IFN- 
was quantified by ELISA. Tests were performed in 2 technical replicates and a representative experiment (of 
n=3) is shown (A). At the same time, the cells were lysed and IFN- contained in the lysates was also determined 
via sandwich ELISA (B). Data are shown ±SD and p-values were determined using Student’s t-test (* p<0.05, ** 
p<0.01, *** p<0.001). 
 
Additionally, we observed a significantly higher percentage of IFN- positive cells after 
silencing of the miR-23a cluster (Figure 31). Thus, endogenous levels of miR-24 and miR-
27a in CD8
+
 T cells could be sufficient to prevent IFN- production in slightly activated cells, 
but may have little effect on cells producing a large amount of IFN-. 
 
Figure 31. Inhibition of miR-23a cluster increased the number of IFN- producing cells. CD8+ T cells were 
isolated and were treated as done in Figure 30. After 44 h these cells were further incubated with monensin for 4 
h and the percentage of IFN- cells was determined by intracellular flow cytometry as described in the Methods 
section. A representative dot plot is shown in (A) while the percentage of IFN- cells (± SD) from 3 
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independent experiments is indicated in (B). p-values were determined using Student’s t-test (* p<0.05, ** 
p<0.01, *** p<0.001). 
Since we had found the miR-23a cluster to be induced by TGF-, we asked whether inhibition 
of these miRNAs also influences IFN- production in the presence of TGF-. In fact, while 
TGF- treatment reduced the number of IFN- positive cells in all groups, the percentage of 
cells remaining positive for IFN- was significantly increased when the cells had been 
transfected with antagomirs before being exposed to TGF- (Figure 32). 
 
 
Figure 32. Inhibition of miRNAs could not rescue the effect of TGF- on IFN- expression. CD8+ T cells 
were isolated and treated as done in Figure 30. Additionally, following nucleofection with antagomirs, each 
group was divided and treated with either TGF-(5 ng/ml), SD-208 (1µM) or left untreated for 12 h. After 48 h 
of activation, IFN- cells were determined by intracellular flow cytometry and their respective percentages were 
plotted. p-values were determined using Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001). 
 
Considering that antagomirs do not affect the known repression of IFN- transcription by 
TGF- (73, 141), more than this partial rescue would have appeared implausible. Thus, 
inhibition of IFN- translation by the TGF--inducible miR-23a cluster apparently constitutes 
a second, indirect mechanism by which TGF- suppresses IFN- production. Nevertheless, 
the miR-23a cluster can inhibit translation of IFN- also in the absence of TGF-. 
5.7 miRNAs from the miR-23a cluster inhibit IFN- expression in Melan-
A-specific CD8
+
 T cells 
So far, we had only analyzed T cells that had been activated by a non-specific TCR-trigger via 
antibody-coated beads. To understand the role of the miR-23a cluster on IFN- production 
following a more physiological and antigen-specific stimulus, we analyzed activation patterns 
of Melan-A-specific CD8
+
 T cells. These cells are derived from purified naïve T cells that 
were primed in vitro using peptide-pulsed dendritic cells and subsequently expanded to yield 
high numbers of T cells with an early effector memory phenotype (129).  
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First we tested whether TGF- was able to induce the miR-23a cluster in these activated and 
expanded cells. Melan-A-specific CD8
+
 T cells were treated with TGF-b or SD208 and the 
miR-23a cluster expression was quantified relative to U6 snRNA. Similar to our results with 
non-specific T cell stimuli in CD8
+
 T cells from peripheral blood, miR-23a, miR-27a and 
miR-24 were also induced by TGF- in this antigen-specific T cell population (Figure 33). 
 
Figure 33. miR-23a cluster is induced by TGF- in Melan-A specific CD8+ T cells. In order to confirm the 
induction of the miR-23a cluster, Melan-A-specific T cells were generated and treated with TGF- (5ng/ml) or 
left untreated (control) for 24 h. miRNA was isolated and the expression of miR-23a, miR-27a and miR-24 was 
determined relative to U6 snRNA by qRT-PCR. Expression levels were normalized to the control and the mean 
normalized expression from 3 experiments is shown. 
 
To functionally investigate the effect of the miR-23a cluster on antigen-specific T cells, 
expanded Melan-A-specific CD8
+
 T cells (purity of 30-50%) were restimulated with 
monocytes pulsed with the Melan-A26-35(A27L) (ELA) peptide, the Melan-A-
overexpressing FM55 cell line or the FM55 cell line pulsed with ELA peptide. Melan-A-
specific CD8
+
 T cells that had been restimulated with the irrelevant WT1 antigen (the HLA-
A2 restricted epitope of Wilms Tumor antigen 1 (126-134)) on monocytes served as negative 
control. Intracellular cytokine staining 4 h after restimulation showed an increased percentage 
of IFN-+ cells when the miR-23a cluster had been suppressed (Figure 34A and 34B) 
whereas overexpression of the cluster did not affect the proportion of IFN--producing cells. 
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Figure 34. Suppression of the miR-23a cluster in restimulated Melan-A specific cells reduces the number 
of IFN- producers. (A) Melan-A specific CD8+ T cells were divided into 2 groups, and nucleofected with 
either 300 nM of antagomir cocktail (containing 100 nM each of antagomirs against miR-23a, miR-27a and miR-
24) or 300 nM antagomir against miR-9. After 48 h, the cells were re-stimulated either with monocytes loaded 
with 1 µg/ml ELA peptide (ELA 1 µg), with monocytes loaded with WTI (unspecific peptide) (WTI), with the 
Melan-A-expressing FM55 (FM55) cell line or with FM55 cells loaded with 1 µg/ml ELA peptide (FM55+ 
ELA1µg). The percentage of IFN- positive cells was quantified by intracellular flow cytometry 4 hours after re-
stimulation in the presence of monensin. Data from 3 independent experiments were pooled and the mean of 
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percentage of IFN- positive cells (± SD) is indicated. Representative dot-plots are shown in (B). p-values were 
determined using Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001). 
 
 We also attempted a prolonged restimulation for 18 h and collected the supernatant from 
these cells. Here we detected significantly higher amounts of IFN- when the miR-23a cluster 
had been inhibited. Conversely, overexpression of the miR-23a cluster reduced the levels of 
secreted IFN- (Figure 35). Controls included the irrelevant antagomir against the non-
expressed miR-9 and the control RNA.  
 
 
Figure 35. Modulation of the miR-23a cluster affects the levels of secreted IFN-g in Melan-A specific CD8
+
 
T cells. Melan-A specific CD8
+
 T cells were divided into 4 groups, and nucleofected with either 300 nM of 
antagomir cocktail (containing 100 nM each of antagomirs against miR-23a, miR-27a and miR-24) or 300 nM 
antagomir against miR-9 or 300 nM of miRNA mimic cocktail (containing 100 nM each of mimic-23a, mimic-
27a and mimic-24) or 300 nM of control RNA. After 48 h, the cells were re-stimulated with monocytes loaded 
with 1 µg/ml ELA peptide (ELA 1 µg), with the Melan-A-expressing FM55 (FM55) cell line or with FM55 cells 
loaded with 1 µg/ml ELA peptide (FM55+ ELA1µg). Supernatants were collected 18 h after re-stimulation and 
secreted IFN- was quantified by ELISA. Shown are mean concentrations of IFN- measured in a representative 
experiment (n=3 independent experiments, measurements performed in triplicate). p-values were determined 
using Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001). 
 
Thus, the experiments performed in this system (which seeks to recapitulate the physiological 
mode of T cell activation) confirmed the previously observed pattern that inhibition of the 
miR-23a cluster increases the percentage of IFN-+ cells whereas transfection with mimics for 
miR-24 and miR-27a reduces the amount of IFN- secreted by highly stimulated CD8+ T 
cells. Moreover, the amount of IFN- detected by ELISA was also increased by the 
antagomirs (which had not been observed with bead-stimulated CD8
+
 T cells). Accordingly, 
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the miR-23a cluster serves as a TGF--inducible set of miRNAs involved in the fine tuning of 
IFN- production in CD8+ T cells.  
5.8 The miR-23a cluster inhibits the cytotoxic activity of antigen-specific 
CD8
+
 T cells 
To study the effect of the miR-23a cluster on the cytotoxic activity of CD8
+
 T cells, we 
analyzed the killing of FM55 (target) cells by Melan-A-specific CD8+ T (effector) cells. We 
used the CellEvent
TM
 Caspase 3/7 Green detection reagent to detect dying cells. This cell 
permeable reagent is cleaved by caspases and rendering it fluorescent, enabling us to quantify 
dying cells by flow cytometry. To this aim, both effector and target cells were co-cultured for 
4 h before the caspase substrate was added. 30 min later, the percentage of FM55 cells 
showing increased Caspase 3/7 activity was determined by flow cytometry. Overexpression of 
the miR-23a cluster using mimics for miR-23a, miR-27a and miR-24 significantly reduced the 
killing capacity of Melan-A-specific T cells when compared to those transfected with the 
control RNA (Figure 36A and 36B). Similar effects on the cytotoxic activity were observed 
when the miR-23a cluster was overexpressed in STEAP specific CD8+ T cells used as 
effectors against STEAP peptide loaded MCF-7 target cells (Figure 36C). 
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Figure 36. miR-23a cluster inhibits CD8
+
 T cell cytotoxicity. (A,B) Melan-A-specific CD8
+
 T cells (purity 
>90%) were nucleofected (program U-014) with 300 nM of either mimics for miR-23a, miR-27a and miR-24 or 
with 300 nM control RNA and seeded in CellGro DC medium with 5% human AB serum and IL-15 (5 ng/ml). 
10
4
 FM55 cells were seeded per well in a 96 well plate. 48 h after nucleofecting the T cells and 24 h after 
seeding the FM55 cells, 10
4
 CD8
+
 T cells from each nucleofected group were harvested, washed and added to 
the wells containing FM55 cells. 4 h later, CellEvent
TM
 Caspase 3/7 Green detection reagent was added at a final 
conc. of 4 µM and incubated for an additional 30 minutes. Wells with only FM55 cells served as a control for the 
basal caspase 3/7 activity in these cells. Cells were harvested, stained with anti-CD8 PE-Cy7 and Caspase 3/7 
activity was measured by flow cytometry. Each condition was assayed in 4 technical replicates and 3 
independent experiments were conducted. The percentage of CD8
low
 cells (± SD) showing caspase 3/7 activity in 
a representative experiment is indicated in (B). (C) The effect of the miR-23a cluster on the cytotoxicity of a 
STEAP-specific CD8
+
 T cell clone (purity > 90%) against STEAP peptide (5 µg/ml) loaded MCF-7 cells was 
assessed using the same experimental protocol as in (A). 
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 Regulation of NKG2D surface expression by TGF-
Context:  
The activating C-type lectin-like receptor natural-killer group 2, member D (NKG2D), 
expressed on NK cells and certain T cell subsets, is crucial for anti-tumor immune responses 
(142). Transformed or stressed cells upregulate (induced) self ligands like major 
histocompatibility complex (MHC) class I chain related (MIC) molecules A and B (MICA, 
MICB) and UL16 binding proteins (ULBP1-6) which can bind and activate NKG2D. In 
humans, activated NKG2D cannot signal on its own but require DAP10. As mentioned 
earlier, NKG2D is expressed on the cell surface complexed to DAP10. Little or no NKG2D 
surface expression is seen without the co-expression of DAP10. Downregulation of NKG2D 
surface expression by tumor secreted TGF- seems to be one of the mechanisms by which 
tumors evade NK and T cell cytotoxicity. However, the mechanisms that drive NKG2D 
suppression are poorly understood.  
 
Results 
5.9.1 NKG2D surface expression on CD8+ T cells and NK cells is reduced by TGF- 
It has been shown that TGF- downregulates NKG2D receptor on CD8+ T cells and NK cells 
in glioma patients (143). Furthermore, serum from colorectal and lung cancer patients, with 
elevated levels of TGF-, reduced NKG2D surface expression and severely impaired NK cell 
functions. In order to test the effect of exogenous TGF- on NKG2D expression of CD8+ T 
cells and NK cells ex vivo, we treated human PBMCs with increasing concentrations (0.15 
ng/ml to 20 ng/ml) of TGF- for 48 h and assessed the levels of NKG2D surface expression 
by flow cytometry. TGF- reduced the surface expression of NKG2D on CD8+ T cells in 
PBMCs in a dose dependent manner (Figure 37). Downregulation of NKG2D reached 
saturation at TGF- concentrations of 2.5 ng/ml and above on both CD8+ T cells and NK 
cells. Hence 5 ng/ml TGF- was used for all experiments. 
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Figure 37: Dose dependent downregulation of NKG2D surface expression by TGF-. PBMCs were freshly 
isolated and were rested overnight (15 h). 1x 10
6
 cells were treated with the indicated concentrations of TGF-. 
After 48 h, cells were harvested and spit into 2 parts. Each part was stained with NKG2D-PE antibody (or an 
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isotype antibody) along with CD3-PE Cy5 and either CD8-FITC or CD56 FITC and analyzed by flow 
cytometry. NK cells were gated on the CD3
low
 CD56
high
 population while CD8
+
 cells were gated on the CD3
high 
CD8 
high
 population and the expression of NKG2D was determined. SFI values were determined by taking the 
ratio of NKG2D-PE median fluorescence to the isotype-PE median fluorescence and are shown for CD8
+
 cells 
and NK cells in the top and middle panels. Bottom panel shows the histogram overlay of control cells and 
5ng/ml TGF- treated cells. 
5.9.2 NKG2D mRNA expression is largely un-altered by TGF- 
To test the effect of TGF- on NKG2D mRNA expression, I isolated and purified CD8+ T 
cells and NK cells (85% to 90% purity) from healthy donor peripheral blood. Cells were 
treated with 5ng/ml TGF- or nothing and were cultured for 24 h. Cells were lysed and cDNA 
was prepared. NKG2D mRNA expression was quantified relative to 18S rRNA. Consistent 
with the findings reported earlier by our group (77) and others (144), NKG2D mRNA 
expression was only slightly affected by TGF- in both CD8+ T cells (p = 0.12) and NK cells 
(p = 0.52) (Figure 38). This pointed towards several possible means of post transcriptional 
inhibition of NKG2D surface expression by TGF-. 
      
Figure 38. NKG2D mRNA regulation by TGF-. CD8+ T cells and NK cells were purified from peripheral 
blood using antibody conjugated magnetic beads as described. Cells were treated with 5 ng/ml TGF- or were 
left untreated. After 24 h, cells were lysed, total RNA was isolated and reverse transcribed into cDNA. 
Expression of NKG2D mRNA was quantified relative to 18S rRNA using SybrGreen based quantitative PCR. 
The experiment was performed using 2 donors and each PCR reaction was done in duplicates. Representative 
data from one of the donors are shown. 
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5.9.3 TGF- signaling does not interfere with reporter gene fused to NKG2D 3’UTR  
Our first guess for post transcriptional regulation of NKG2D was the involvement of miRNAs 
that could bind the 3’UTR of its mRNA. To this end, a pMIR-NKG2D 3’UTR construct was 
cloned and generated by Dr. Lasse Weinmann at the Max Planck Institute of Biochemistry, 
Martinsried, Munich, Germany. In short, NKG2D 3’UTR was amplified from the cDNA of 
human lymphocytes using primers containing restriction sites for either Sac1 or Nae1. 
NKG2D 3’UTR SacI fwd: ATCTGAGCTCAGATGATCAACCATCTCAATAAAAGC 
NKG2D 3’UTR NaeI rev: ATCT GCCGGCGCATGAGACTCAAGATTCTATTTATTC. 
The amplified 776 bp 3’UTR fragment was then fused to the pMIR-RL (modified with HSV-
TK promoter) plasmid between the Nae1 and Sac1 sites. PBLs from healthy donors were 
nucleofected with either pMIR-NKG2D or with the control plasmid pMIR-RL. Cells were 
then treated with TGF- (5 ng/ml), SD208 (1 µM) or were left untreated for 24 h. No 
reduction of firefly luciferase activity was observed after TGF- treatment and thus we 
dismissed the hypothesis that TGF- induced miRNAs were interfering with the 3’UTR of 
NKG2D (Figure 39). 
             
Figure 39: TGF- does not target NKG2D 3’UTR. 5x 106 PBMCs were nucleofected with 1 µg/100 µl of 
either pMIR-NKG2D or pMIR-RL plasmids. After 1 h, 1x 10
6
 cells were treated in triplicates with TGF- (5 
ng/ml), SD-208 (1 µM) or were left untreated for 24 h. Cells were harvested and lysed in 100 µl 1X Reporter 
lysis buffer (Promega). After one freeze-thaw cycle at -20°C, firefly and Renilla luciferase activities were 
measured. Ratio of background subtracted firefly to Renilla luciferase counts was calculated to normalize 
transfection efficiency. Luciferase counts from the pMIR-NKG2D transfected cells were then normalized to 
those transfected with pMIR-RL. Experiment was performed 3 times and a representative experiment is shown 
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5.9.4 TGF- inhibits DAP10 mRNA and protein expression 
Due to the fact that NKG2D is rarely expressed without DAP10 on the cell surface we turned 
our focus towards the accessory signaling protein DAP10, which is associated with NKG2D 
in human cells. Microarrays comparing TGF- treated vs untreated NK cells, prepared by my 
former colleague (Dr. Yvonne Dombrowski), showed that DAP10 mRNA was downregulated 
in TGF- treated NK cells (Figure 40A). To further confirm this effect, we quantified DAP10 
mRNA using qRT-PCR on NK cells treated with or without TGF- and found that DAP10 
mRNA was indeed less after TGF- treatment (Figure 40B). We then checked whether the 
negative effect of TGF- on mRNA was reflected in DAP10 protein expression. Protein 
lysates from TGF- treated (48 h) or untreated NK cells when analyzed by immunoblotting 
indicated that DAP10 protein expression was in fact inhibited by TGF- (Figure 40C).  
 
 
      
 
Figure 40: Regulation of DAP10 by TGF-. (A). NK cell microarrays were prepared as described in Materials 
and methods. The fold expression change of DAP10 mRNA after TGF- treatment relative to the untreated 
group is shown. (B) NK cells were magnetically purified from peripheral blood of healthy donors (n=3) and 
were treated with 5 ng/ml TGF- or were left untreated. RNA was isolated after 24 h and the level of DAP10 
mRNA was quantified relative to 18S rRNA as described. qRT-PCR was performed using duplicates and 
representative results from 1 of 3 donors are shown. (C) Purified NK cells were either treated with either TGF- 
(5ng/ml) or SD-208 (1 µM) or were left untreated for 48 h. Protein lysates were prepared and DAP10 protein 
expression was visualized by immunoblotting. 
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5.9.5 Does TGF- inhibit NKG2D surface expression by downregulating DAP10? 
To answer this question, we tried to ectopically overexpress DAP10 to rescue NKG2D 
expression in the presence of TGF- in primary NK cells as well as NKL and NK92 cell lines. 
Given the difficulty of transfecting these cells, instead of conventional reagents and 
nucleofection techniques, we decided to use retroviral and lentiviral transductions. We 
received pLPCX-DAP10-GFP (145) plasmid from Prof. Dr. Hugh Reyburn (Division of 
Immunology, University of Cambridge, UK). This plasmid was co-precipitated along with 
pHIT60 and pVSV-G and transfected into HEK293T cells to generate the retrovirus which 
was then used for retroviral transduction of NK cells and NKL cell lines (146). We also 
subcloned DAP10-GFP into a pCDNA3.1 backbone and nucleofected these cells with it. 
Analyzing the expression of GFP using flow cytometry, both retroviral transduction and 
nucleofection of NK and NKL cells yielded < 5% efficiency. We are also unsuccessful in 
infecting NK cells using lentiviral vectors. Since our lab does not meet S2 safety regulations, 
viral transductions were conducted at the Institute for Virology and Immunology, Würzburg, 
under the supervision of Prof. Thomas Hermann and at the Department of Dermatology, 
Würzburg with the help of Dr. Roland Houben. However due to several practical difficulties, 
we were unsuccessful in ectopically expressing DAP10 in NK cells. Still, the idea and 
hypothesis are testable once robust NK cell transfection techniques have been developed.  
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6 Discussion 
6.1 Induction of the miR-23a cluster by TGF- and functional 
characterization of its immunomodulatory functions. 
Within and around our body are an overwhelming amount of pathogens and foreign particles 
which can potentially kill us. On top of this are our own cells that can transform to enter 
uncontrollable cell divisions thereby causing life threatening cancers. Yet we are kept alive as 
a result of controlled interactions of our immune system with those external and internal 
agents. Equally important is the control of self antigen reactions through peripheral tolerance 
mechanisms, the most pronounced being displayed towards the maintenance of our gut 
microbiota (147). T cell mediated immunity essentially has evolved into a fine-tuned multi-
level system which enables us to interact and adjust ourselves with our environment. T cells 
and NK cells mediate anti-cancer immune responses by eliminating cancer cells through 
different ways; T cells mediate anti-cancer antigen specific responses while NK cells detect 
and eliminate cells that show signs of transformation or stress. Cancers also evolve 
mechanisms of immune evasion by mutating or shedding stress activated ligands, 
downregulating HLA-A molecules and secreting immunosuppressive cytokines. Lately, 
miRNAs have been identified to play a role in the cancer vs immune system battle. Many 
solid tumors are infiltrated by immune cells that are often unable to mount functional 
responses. Immunosuppressive miRNAs that are induced by the tumor microenvironment in 
tumor infiltrating immune cells can dampen responses of activated T cells. This study mainly 
focused on immunosuppressive miRNAs induced by TGF-. 
In the initiation of a T cell response, naïve CD8
+
 T cells get primed by antigen-presenting 
cells in the lymph node, expand in an antigen-specific manner and differentiate while gaining 
effector functions. After migration towards peripheral tissues, renewed antigen-contact should 
lead to IFN- production (148), to activation of further cytotoxic effector mechanisms and to 
the elimination of the antigen-expressing cell. At immune-privileged sites or in a tumor 
microenvironment, however, peripheral tolerance mechanisms need to be considered. In fact, 
the ability to escape from immune-mediated destruction has recently been named as a 
hallmark of cancer (149). In this context, the most potent of all immunosuppressive cytokines, 
namely TGF-, deserves special attention as it is frequently secreted by tumor cells (150). 
Transcriptional effects of TGF- on CD8+ T cells have already been analyzed in great detail 
(73). Still, we hypothesized that TGF--dependent immunomodulation might operate at 
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several levels and thus explored a potential contribution of miRNAs in this context. Hence, 
we investigated miRNA changes induced by TGF- in pre-activated CD8+ T cells in vitro, 
using both bead-based stimulation via CD3, CD28 and CD2 and antigen-specific CD8
+
 T cell 
activation and expansion via peptide-loaded antigen-presenting cells. 
To obtain an overview over miRNA regulations induced by TGF-, we first analyzed miRNA 
profiles in activated CD8
+
 T cells that had been treated or not with TGF- for 24 h. In order to 
recognize effects from endogenous TGF- signaling, a further control treated with the TGF- 
receptor I kinase inhibitor SD-208 (125) was included. For sequencing or microarray analysis, 
the total amount of RNA was increased by pooling of several donors which also helped to 
even out extreme individual responses, to facilitate the detection of rare miRNA species and 
to keep costs at an affordable level. To ensure that the TGF- that we added was functional 
we checked the phosphorylation of SMAD-2/3 by immunoblotting as well as tested for the 
downregulation of NKG2D surface expression (Figure 12). 
While a recent systematic cross-platform comparison (134) showed that different techniques 
lead to different results, the comparison between the different techniques was not a primary 
aim of our study. Hence, the cross-validation was based on biological rather than merely 
technical replicates. 13 miRNAs that were found to be regulated in both microarrays and 
sequencing libraries (displaying a similar tendency) (Table 3) were then further validated by 
qRT-PCR, using individual T cell samples from various donors (Table 4). Accordingly, we 
could focus on those miRNAs that showed consistent regulations by all three approaches. 
Next generation sequencing of CD8
+
 T cell miRNAs also enabled us to detect new miRNA 
candidates based on their abundance, secondary structure patterns and free energy of folding 
(see 5.1.3). While most these sequences still have to be further evaluated, one has meanwhile 
been added to the Sanger miRNA database as miR-1280 and later retracted. One of the 
sequences showed about 80% homology to cer-miR-248 stem loop. 
However, our primary focus was on the miR-23a cluster. Among all miRNAs that were 
regulated by TGF- the miR-23a cluster stood out since all three co-transcribed miRNAs 
(miR-23a, miR-27a and miR-24) were present in reasonable copy numbers (relative 
abundance was 2.25% for miR-23a, 3.5% for miR-27a and 0.67% for miR-24) and were 
uniformly increased after addition of TGF-, irrespective of the detection method, the donor 
and the mode and extent of T cell pre-activation. Hence, these regulations are unaffected by 
the Ago-dependent global changes in miRNA expression during T cell activation which have 
recently been described (151). Moreover, similar regulations were also found in murine CD8
+
 
T cells from Balb/cJ wild-type mice, but not in CD8
+
 T cells from hCD2-∆kTRII mice 
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which express a dominant-negative TGF- receptor under the control of the CD2 promoter 
(Figure 18). Though the level of induction may appear rather low (and would hardly appear 
relevant for mRNAs) after 24 h of TGF- treatment, similar changes in miRNA expression 
have repeatedly been observed to yield functionally significant effects (152, 153). 
Furthermore, the induction of the miR-23a cluster when monitored over 72 h indicated a 
continued accumulation of all 3 cluster members within CD8
+
 T cells (Figure 17). This can 
cause a compounding and persistent effect on the known early transcriptional regulations of 
TGF- target genes (significance of which is discussed later). Known effects of the miR-23a 
cluster include the modulation of apoptosis and proliferation via targeting of XIAP, FADD 
and PTEN (154-156). While these proteins are also interesting in connection with TGF-, we 
screened >1,000 potential targets predicted by computational methods for candidates that 
could contribute to the effects of TGF- on CD8+ T cell effector functions and focused our 
attention on CD107a/LAMP1 and IFN-. Although not predicted by the various mentioned 
tools, we also tested the effect of miR-23a cluster on other T cell effector molecules like 
granzyme B, perforin and Fas-L. However, the miR-23a cluster members did not affect the 
expression of granzyme B, perforin and Fas-L upon T cell activation. 
Significant effort was put into selecting an appropriate transfection method for T cells that 
was minimally toxic yet sufficiently effective in delivering plamid DNA and small RNA 
molecules like antagomirs and miRNA mimics. Nucleofection proved the best with >70% 
transfection efficiency by preserving the ability of cells to respond to activation stimuli. Still, 
to study molecular interactions of miRNAs to complementary regions on target mRNA 
3’UTRs, we performed luciferase-reporter gene assays using the HEK293 T cell line for its 
relative ease of culture and transfection using conventional reagents. 
LAMP1 is an essential component of the cytotoxic granule membrane which prevents the 
granule content from damaging the host cell. While little is known about the regulation of 
LAMP1, TGF- reduces the cytotoxic potential of CD8+ T cells (73) which would be 
consistent with a miRNA effect on LAMP1 translation. Moreover, the 3´-UTR of LAMP1 
contains two putative binding sites for the TGF--inducible miR-23a. The 3´-UTR of IFN-, 
in contrast, contains predicted binding sites for the further members of the miR-23a cluster: 
two for miR-27a and one binding site for miR-24 (Figure 19). In addition, IFN- is known to 
be affected by TGF-. A transcriptional mechanism of inhibition operating via Smad2/3 and 
ATF1 has already been dissected on molecular level (73) and a TGF--dependent reduction of 
IFN- mRNA stability has been observed in the murine NK cell line LNK5E6 (157). Using 
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luciferase-based reporter gene assays, we could show direct effects of miR-23a on the 3´-UTR 
of LAMP1 and of miR-24 and miR-27a on the 3´-UTR of IFN- (Figure 22 and 23). 
Specificity was further confirmed by mutation of the predicted binding sites. Thus, the in 
silico predictions could be experimentally validated. Synergy effects between the two 
miRNAs targeting the 3´-UTR of IFN- were not observed which may be due to all 
transfections being performed with a constant total amount of miRNA mimics. Further, 
binding of one miRNA to the target 3´UTR should already suffice to inhibit translation. Most 
importantly, however, simultaneous modulation of all three cluster members is the most 
physiological approach as the miRNAs in the cluster are co-expressed from a single 
polycistronic RNA. Here it has to be noted that the pMIR-RL plasmid that we used drives the 
expression of the miRNA sensitive luciferase gene using the HSV-TK promoter which has a 
rather modest activity when compared to other viral promoters (e.g. CMV). This enables the 
detection of subtle miRNA activities. 
After these proof-of-principle assays which were performed in HEK293T cells, we sought to 
explore the functional relevance in primary human CD8
+
 T cells (which display about 8-fold 
higher endogenous levels of miRNAs than the HEK293 T cells used for reporter gene assays). 
However, while primary CD8
+
 T cells are clearly most relevant for our study (and unaffected 
by compensation or adaptation processes that could obscure effects in genetic models), they 
are relatively difficult to transfect. Control experiments were performed to ensure that the 
delivery of antagomirs and miRNA mimics could be achieved by nucleofection. 
Consequently, these tools were found to be suitable for further assays, although nucleofection 
is somewhat stressful for the cells and miRNA inhibition by antagomirs is never more than 
partial. In particular, one has to be aware that effects can be “diluted” by the contribution of 
cells which do not take up the nucleofected oligonucleotides. Furthermore, we included 
antagomirs against the non-expressed miR-9 as well as the All stars negative control RNA 
alongside the experimental nucleofections as relevant controls. 
With regard to LAMP1, functional results were somewhat equivocal: A degranulation assay 
in the presence of anti-CD107a/LAMP1 antibody and monensin revealed that inhibition of the 
miR-23a cluster can indeed increase the amount of LAMP1 at the surface of degranulating 
cells. Moreover, total LAMP1 levels were hardly modulated during T cell activation when 
monitored by immunoblotting (Figure 24). This could be due to a low turnover of LAMP1 
protein and to the presence of large intracellular reservoirs – which was confirmed by addition 
of the translation inhibitor cycloheximide to stimulated CD8
+
 T cells (Figure 25). Considering 
that nucleofected T cells can´t be maintained much longer in vitro, effects of miR-23a on 
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LAMP1 should ultimately be clarified in (ideally T cell specific and inducible) miR-23a 
knock-out animals in vivo. Based on the in vitro data obtainable from human cells, the 
selective effect on cell surface LAMP1 could be explained by the co-existence of different 
pools of LAMP1 in the cell, with granule formation requiring freshly translated LAMP1. 
Alternatively, the highly promiscuous nature of miRNAs would also allow for an additional 
interaction of miR-23a with a factor required for granule trafficking or fusion with the plasma 
membrane. Irrespective of these considerations, our data show that miR-23a interacts with the 
3´UTR of LAMP1 and decreases LAMP1 cell surface expression. 
Clearer results were obtained on the regulation of IFN-in CD8+ T cells. Interestingly, in 
bead-stimulated polyclonal CD8
+
 T cells inhibition of autocrine miR-23a cluster expression 
increased the number of IFN--positive cells upon stimulation and the amount of intracellular 
IFN-, though there was no effect on the much higher IFN-levels in the supernatant (Figure 
30). Conversely, overexpression of miR-23a cluster led to a considerable reduction of total 
IFN- levels whereas the number of IFN--producing CD8+ T cells remained unchanged 
(Figure 28). These findings invite for speculations on the dynamics of IFN- production in 
heterogeneous polyclonally activated T cell populations. Clearly, some cells do not produce 
IFN-, and these non-producers cannot respond to miRNA inhibition. However, a proportion 
of cells may be at the brink of getting activated. In these cells, small amounts of IFN- mRNA 
might already be present while translation could still be prevented by autocrine miR-23a 
cluster expression. Inhibition of endogenous miR-24 and miR-27a could then initiate IFN- 
production and thus explain the increase in IFN- producing cells after transfection with 
antagomirs. Finally, a further population of highly activated cells may have overcome 
inhibitory effects of endogenous miR-24 and miR-27a expression, possibly by producing 
IFN- mRNA in excess. In these, IFN- mRNA might simply outcompete the number of 
miRNA transcripts.  As these cells will secrete large quantities of IFN-, they will largely be 
responsible for the amount of IFN- in the supernatant. Transfection of such IFN- “high 
producers” with miRNA mimics would then reduce the amount of IFN- in the supernatant 
without altering the percentage of IFN--positive cells. Such a pattern could be due to the 
simultaneous occurrence of different activation stages in the polyclonal culture and/or to the 
simultaneous presence of different subtypes of CD8
+
 T cells with different capacities for 
producing IFN-(158). This invites further experiments to analyze the effect of the miR-23a 
cluster on different T cell subsets. 
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We then chose in vitro expanded antigen-specific T cells with a well characterized early 
effector memory phenotype (129). In this system, the effect of the miRNA mimics on IFN- 
secretion and the increase in the number of IFN-+ CD8+ T cells after transfection with the 
antagomirs was confirmed. Moreover, while endogenous expression levels of miR-23a cluster 
members were very similar between bead-stimulated and antigen-specifically expanded CD8
+
 
T cells, assays in this more physiological setting revealed a previously unrecognized effect of 
the antagomirs on the total amount of secreted IFN-(Figure 35) An explanation might be 
found by investigating IFN- mRNA and miR-23a cluster expression on an individual per cell 
basis which, however, would have been beyond the scope of this study.     
We further assessed the effect of inhibiting the miR-23a cluster in CD8
+
 T cells that were 
subsequently treated with TGF-. As TGF- is known to reduce IFN- production via 
transcriptional repression, antagomirs could not prevent this reduction. Nevertheless, the 
effect of TGF- was attenuated in the presence of antagomirs. Induction of the miR-23a 
cluster by TGF- thus seems to amplify the transcriptional effect on IFN- and may be 
involved in fine tuning of the response. In addition, miRNAs have a tendency to persist and 
accumulate. Carrying on from what was discussed earlier, the highest expression of the miR-
23a cluster was found from 72h up to 5 days after TGF- treatment which suggests that 
induction of the miR-23a cluster and its effect on IFN- and LAMP1 can persist well beyond 
24 h (when the miRNA arrays and deep sequencing were performed) and can prolong the 
effect of TGF- beyond the duration of the transcriptional repression. 
Finally, we used both polyclonal Melan-A-specific T cells and a STEAP-specific T cell clone 
to investigate whether the miR-23a cluster affects CD8
+
 T cell cytotoxicity against tumor cell 
targets. Compared to nucleofection with an irrelevant control RNA, nucleofection with the  
miR-23a cluster reduced the killing capacity of cytotoxic T cells to approximately half, both 
for the polyclonal Melan-A-specific T cells and for the cytotoxic T cell clone. Moreover, the 
effect was observed both with FM55 melanoma cells showing endogenous Melan-A 
expression and with STEAP peptide loaded MCF-7 breast cancer cells.  
Thus, our study led from a broad screening of TGF--dependent miRNA regulation in 
primary human CD8
+
 T cells and confirmation in a transgenic mouse model to a previously 
unrecognized immunomodulatory mechanism of the miR-23a cluster which likely adds to the 
immunosuppressive properties of TGF-. Apart from an effect of endogenous miR-23a 
cluster expression on the proportion of IFN--positive cells in activated CD8+ T cells, we 
could also show effects of miR-23a on the availability of LAMP1 on the surface of cytotoxic 
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granules. Most importantly, overexpression of the miR-23a cluster attenuated the cytotoxic 
potential of antigen-specific CD8
+
 T cells. Consequently, the role of the miR-23a cluster in 
CTL and its link to TGF- signaling deserves further investigation in suitable disease models 
in vivo. Moreover, since distinct miRNA profiles have been associated with several cancers, 
the changes in the miRome CD8
+
 T cells caused by exogenous TGF- might correlate with 
those of cancers which secrete high levels of this cytokine. Hence the deep sequencing data 
and miRNA arrays that we generated need to be computationally analyzed for such 
correlations. Apart from miRnome profiles being just biomarkers for diseases, modulation of 
individual miRNAs has been shown to induce certain diseases. Thus, therapeutic targeting of 
miRNAs is a promising and upcoming area of research. Direct modulation of miRNAs to 
effect tumor remissions have already succeeded in mice. Although delivery of miRNAs in 
vitro have been effectively developed, in vivo administration and site directivity of miRNA 
expression modulators is the key issue. miRNAs also hold the potential to act as supporting 
agents to act as sensitizers in current therapeutic regiments. Having said these, the 
immunosuppressive functions of the miR-23a cluster make them a therapeutically interesting 
miRNA cluster which can be targeted to improve anti-tumor immune responses.  
6.2 Regulation of NKG2D/DAP10 surface expression by TGF- 
Our experiments indicated that NKG2D mRNA expression was hardly modulated by TGF-
in NK cells (Figure 38). Reporter gene assays showed the lack of any post transcriptional 
regulations (by miRNAs) targeting NKG2D 3’UTR (Figure 39). Interestingly in NK cells, 
mRNA arrays as well as qRT-PCR showed a downregulation of DAP10 mRNA upon addition 
of TGF-. Thus we hypothesize that TGF- modulates NKG2D surface expression via 
suppression of DAP10 rather than NKG2D directly. To validate this, we tried to ectopically 
overexpress DAP10 in NK cells to rescue NKG2D surface expression in the presence of TGF-
. Unfortunately, we were unable to overcome the difficulties associated with transfecting 
DAP10 into primary NK cells using nucleofection or retroviral vectors. Among NK cells 
lines, YT cells could readily be transfected whereas NK-L and NK92 cells resisted the 
attempted gene transfer. YT cells do, however, lack NKG2D expression which means that 
they do not represent a suitable model for the posed question. Still, upon availability of an 
efficient NK cell transfection system, our hypothesis concerning the DAP10-dependent 
regulation of NKG2D surface expression would deserve further exploration. 
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8 Abbreviations 
°C degree Celsius LAMP lysosome associated membrane protein 
µg microgram LNA Locked nucleic acid 
µl microliter MACS Magnet assisted cell sorting 
µM micromolar mg milligram 
APC Allophycocyanin MHC Major histocompatibility complex 
BSA Bovine serum albumin min minute (s) 
CD Cluster of differentiation ml milliliter 
cDNA complementary DNA mM millimolar 
CTL Cytotoxic T lymphocyte ng nanogram 
DAP DNAX activation protein NK cells Natural Killer cells 
dd double distilled nm nanometer 
DN Double negative PBMC Peripheral blood mononuclear cell 
DNA Deoxyribonucleic acid PBS Phosphate buffered saline 
DP  Double positive PCR polymerase chain reaction 
EDTA Ethylenediaminetetraacetic acid PE Phycoerythrin 
ELISA Enzyme-linked immunosorbent assay PMSF phenylmethanesulfonyl fluoride 
FBS Fetal bovine serum RISC RNA induced silencing complex 
FITC Fluorescein isothiocyanate RNA Ribonucleic acid 
h hour (s) rpm revolutions per minute 
HRP horse radish peroxidase RPMI Roswell Park Memorial Institute 
hsa Homo sapiens s second (s) 
HSA human serum albumin SDS Sodium dodecyl sulphate 
IFN Interferon Smad Sma mothers against decapentaplegic 
IL Interleukin TCR T cell receptor 
IMDM Iscove's Modified Dulbecco's Medium TGF Transforming growth factor 
IU International units UTR Untranslated region 
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